EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2017

 

19-23 April 2017 Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  THU-001 Risk factors of early emergent hospital readmission and 6-month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection Filippo Morando Received Received
  SAT-001 Human umbilical cord mesenchymal stem cell treatment improves survival rate in patients with decompensated liver cirrhosis Ming Shi Received Received
  SAT-002 Cirrhosis and acute on chronic liver failure: is ammonia a predictor of hepatic encephalopathy and mortality? Mohammed Sheikh Received Received
  THU-002 Pregnancy in women with idiopathic non-cirrhotic portal hypertension: results of a multicentric European study on maternal and fetal management and outcome Filipe Teixeira Andrade Received Received
  FRI-002 Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis Florian Rainer Received Received
  FRI-003 Non malignant portal vein thrombosis in cirrhotic patients: is the anticoagulation safe and efficient? Gargouri Dalila Received Received
  THU-003 Von Willebrand Factor as a predictor of short-term morbidity and mortality in comparison with conventional scoring systems Aditya Vivekanand Kulkarni Received Received
  THU-004 Early initiation of carvedilol is safe and cost effective in cirrhotic patients presenting with upper GI bleed following endoscopic therapy: results of a prospective randomized trial Adnan Salim Received Received
  SAT-004 Prolonged intensive care support of patients with acute on chronic liver failure and CLIF-C ACLF score greater than 70 may be futile Nekisa Zakeri Received Received
  SAT-005 Transjugular intrahepatic portosystemic shunt before planned abdominal surgery in cirrhotic patients Nicolas Tabchouri Received Received
  THU-005 Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis Agostino Colli Received Received
  FRI-006 Validation of the Baveno VI criteria for the screening of gastroesophageal varices in our hospital Gema Molina Arriero Received Received
  THU-006 Rapid change of liver stiffness after variceal ligation and TIPS implantation Felix Piecha Received Received
  SAT-006 Farnesoid-X Receptor single nucleotide polymorphism rs35724 is potentially associated with patients` outcome in decompensated liver cirrhosis Cornelius Engelmann Received Received
  SAT-007 The long-term impact of sustained virologic response (SVR) on patient-reported outcomes (PROS) in cirrhotics with Hepatitis C (HCV) infection Zobair M Younossi Received Received
  FRI-007 Abnormal MOCA scores are common and predict morbidity and mortality in patients with cirrhosis Michael Ney Received Received
  THU-007 A chronic disease management model for chronic liver failure is cost-effective; cost-effectiveness analysis Alan J Wigg Received Received
  THU-008 Spontaneous bacterial empyem revisited Alberto Amador Received Received
  FRI-008 Porto- systemic shunt embolization and recurrent ascites: a single centre case series Graziella Privitera Received Received
  SAT-008 Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials Nina Kimer Received Received
  FRI-009 Early recurrent overt hepatic encephalopathy is associated with poor survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt Guohong Han Received Received
  THU-009 Outcome of liver transplant recipients after the first episode of bacterial infection Alberto Ferrarese Received Received
  SAT-009 New classification of gastric varices: a twenty-year experience Nipun Verma Received Received
  THU-010 Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution Alberto Zanetto Received Received
  FRI-010 Hepatic encephalopathy in cirrhotic patients with bacterial infections: prevalence, clinical characteristics and correlation with prognosis: a prospective study Gustavo Henrique Santos Pereira Received Received
  FRI-011 Serum creatinine level is not appropriate in predicting prognosis in patients with liver cirrhosis and sarcopenia Han Ah Lee Received Received
  THU-011 Long-term survival after hospital discharge in cirrhotic patients previously hospitalized in intensive care unit for an acute event: a 6 year cohort study Fabien Marquion Received Received
  SAT-011 Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF Vinod Arora Received Received
  SAT-012 Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis Vincenza Calvaruso Received Received
  THU-012 Usefulness of the six-minute walk as a predictor of mortality in patients with decompensated cirrhosis Ernesto Marquez Guillen Received Received
  FRI-012 time in HE in cirrhotic patients with an acute episode (=grade 2) determines short and long-term survival Meritxell Ventura Cots Received Received
  FRI-013 Palliative care access for hospitalized patients with end stage liver disease across the United States Mayur Brahmania Received Received
  THU-013 High serum human beta-defensin-1 is associated with increased short-term mortality in patients with decompensated cirrhosis Alexandra Alexopoulou Received Received
  THU-014 Prospective study of gastrointestinal tract colonization with multidrug resistant bacteria and potential association with infection development and survival in patients with decompensated cirrhosis Alexandra Alexopoulou Received Received
  FRI-014 Cirrhotic patients in ICU with gastro-intestinal bleeding managed according to recent guidelines display altered brain hemoglobin oxygen´s saturation assessed by near infrared spectroscopy Maxime Mallet Received Received
  SAT-014 Decrease in cardiac work in patients with alcoholic hepatitis: role of inflammation? Olivier Roux Received Received
  FRI-015 Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity Mattias Mandorfer Received Received
  THU-015 Single center validation of scores for prediction of mortality in patients with acute-on-chronic liver failure or acute decompensation of cirrhosis without acute-on-chronic liver failure Alexandra Alexopoulou Received Received
  SAT-015 PALBI - the platelet-albumin-bilirubin score – a better predictor of outcome of acute variceal bleeding Omar Elshaarawy Received Received
  THU-016 Uncontrolled glycaemia increases the risk of developing spontaneous bacterial peritonitis in patients with cirrhosis Fatima Higuera-de La Tijera Received Received
  FRI-016 Performance of FibroScan to detect large esophageal varices in chronic liver diseases is improved by a novel spleen-dedicated examination Horia Stefanescu Received Received
  SAT-016 Prevalence and clinical impact of rectal colonization by multidrug-resistant bacteria in critically ill patients with and without cirrhosis Veronica Enith Prado Gonzalez Received Received
  SAT-017 Real world impact of rifaximin-a use in hepatic encephalopathy patients with advanced liver disease or continued alcohol misuse: a post-hoc analysis of the IMPRESS study Paola Di Maggio Received Received
  THU-017 Metabolic risk factors increase the risk of hepatocellular carcinoma in patients with hepatitis C cirrhosis Alina Kutsenko Received Received
  FRI-018 Presepsin (soluble CD14 subtype) levels in cirrhotic patients with bacterial infections and/or portal hypertension related bleeding presented with or without acute kidney injury Ioannis S Elefsiniotis Received Received
  SAT-018 The addition of splenic and superior mesenteric vein respiratory excursions to Baveno VI criteria can save more endoscopies without compromising its diagnostic accuracy Paolo Del Poggio Received Received
  THU-018 GAVE is more common in patients with NASH-cirrhosis Aline LeCleac´h Received Received
  SAT-019 Screening of large esophageal varices by a simple algorithm of blood markers Paul Cales Received Received
  THU-019 Mortality of variceal bleeding admitted to the intensive care unit: an Australasian study Ammar Majeed Received Received
  FRI-019 Adipocyte fatty acid binding protein in cirrhosis: increased hepatic gene expression and plasma levels and correlation with clinical outcomes Isabel Graupera Received Received
  FRI-020 A multimodality assessment of liver fibrosis in asymptomatic Fontan patients Isabelle Munsterman Received Received
  SAT-020 Fat mass and visceral fat inversely correlate with disease severity in patients with liver cirrhosis - a Bioelectrical impedance analysis based study Varsha Shasthry Received Received
  THU-020 C reactive protein contributes to the early prediction of 90-day mortality risk in acutely decompensated cirrhotic patients Ana Clemente Received Received
  THU-021 Hepatic and non-hepatic events after obtaining a SVR in patients with genotype 1b liver cirrhosis-short time follow-up-single center experience Ana Maria Singeap Received Received
  FRI-021 Short-term metabolic alterations following liver transplantation Iva Košuta Received Received
  THU-022 The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy Andrei Mihai Voiosu Received Received
  FRI-022 NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients Jacqueline G Oleary Received Received
  SAT-022 DASIMAR - a novel prognostic biomarker for acute cirrhosis decompensation to guide early intervention - a prospective multicenter study Peter Holland-Fischer Received Received
  SAT-023 For diagnosis of acute kidney injury in decompensated cirrhosis the estimation of baseline serum creatinine using Modification of Diet in Renal Disease formula is not accurate enough Petra Fischer Received Received
  THU-023 Adverse events and the development of acute on chronic liver failure in patients with cirrhosis undergoing endoscopic retrograde cholangiopancreatography: A retrospective, multicenter, case-control study Andres Cardenas Received Received
  FRI-023 When to refer end-stage liver disease patients to palliative care: a survey of practicing liver and palliative care clinicians James Philip Esteban Received Received
  FRI-024 An Innovative app focused on patients and caregivers significantly decreases avoidable and HE-related readmissions in cirrhotic patients Jasmohan Singh Bajaj Received Received
  THU-024 Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial Angela Horvath Received Received
  SAT-024 The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease Philip Georg Ferstl Received Received
  THU-025 Prevalence of portal trombosis related to the degree of portal hypertension Joaquin Cabezas Gonzalez Received Received
  FRI-025 Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients Jasmohan S Singh Bajaj Received Received
  THU-026 The natural history of covert hepatic encephalopathy in cirrhotic patients in a tertiary care hospital Anjiang Wang Received Received
  FRI-026 Oral glutamine challenge predicts risk and defines hepatic encephalopathy types Javier Ampuero Received Received
  SAT-026 Hepatocyte microvesicle levels predict 6-month survival in patients with cirrhosis: results of a prospective study on 242 patients Pierre-Emmanuel Rautou Received Received
  FRI-027 Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis Javier Fernandez Received Received
  THU-027 Long-term prognosis following acute-on-chronic liver failure Eileen L. Yoon Received Received
  SAT-027 Modification of deranged systemic hemodynamic parameters and impaired intestinal permeability with slow infusion of furosemide and albumin with or without terlipressin in patients with refractory ascites Prabhat Narain Sharma Received Received
  THU-028 Clinical significance of urinary neutrophil gelatinase-associated lipocalin measurement in differentiating various etiologies of acute kidney injury in cirrhotic patients Eileen L. Yoon Received Received
  FRI-028 The Quick SOFA, a simple bedside score, identifies hospitalized cirrhotic patients with poor outcomes Jean-Paul Cervoni Received Received
  SAT-028 Impact of antiviral treatment in patients with HCV cirrhosis: a reduction in hospital admission rates Prashant Bamania Received Received
  SAT-029 Occult advanced fibrosis in the general population Rifaat Safadi Received Received
  THU-029 Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention Annalisa Berzigotti Received Received
  SAT-030 Carvedilol is associated with improved survival in patients with decompensated cirrhosis Rohit Sinha Received Received
  THU-030 L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials Ee Teng Goh Received Received
  THU-031 Nutritional habits in patients with chronic liver disease: adherence of real life diet to international guidelines and its association with disease stage Edoardo Poli Received Received
  SAT-031 Frequency and causes of malnutrition in liver disease patients: results from a multi-centric cross-sectional survey from gastroenterology tertiary clinics Roxana Vadan Received Received
  FRI-031 Performance of upper gastrointestinal bleeding risk assessment scores in variceal bleeding: a prospective international multicenter study Yung Ka Chin Received Received
  THU-032 Resistant bacterial infections in cirrhosis: a French observational prospective multicentre nationwide study (RESIST study) Arnaud Pauwels Received Received
  SAT-033 Assessment of Sepsis-3 criteria in patients with cirrhosis and bacterial infections Salvatore Piano Received Received
  FRI-033 Acute hemodynamic response to beta-blockers: factors influencing its outcome Antonio Cuadrado Lavin Received Received
  FRI-034 Patients with alcoholic-related cirrhosis have high burden of coronary arteriosclerosis compared to non-alcohol-related cirrhosis Karen Vagner Danielsen Received Received
  THU-034 Systematic review with meta-analysis: liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding Astrid Marot Received Received
  SAT-034 Impact of acute-on-chronic liver failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome Salvatore Piano Received Received
  SAT-035 Prediction in-hospital mortality of acute esophagogastric variceal bleeding: which is the best score? Sara Monteiro Received Received
  THU-035 A new classification of chronic portal vein occlusion for assessing the feasibility of recanalization in non-cirrhotic patients Astrid Marot Received Received
  FRI-036 Medication beliefs predict low medication adherence in people with decompensated cirrhosis Kelly Lee Hayward Received Received
  THU-036 Bioelectrical impedance vector analysis is an objective method for nutritional assessment in patients with cirrhosis Astrid Ruiz-Margáin Received Received
  THU-037 Comparison of heterozygous alpha-1 antitrypsin deficiency in unselected patients with liver cirrhosis and transplant recipients with the general population and liver donors Benedikt Schaefer Received Received
  FRI-037 The association between serum sodium and rate of hepatic encephalopathy in cirrhosis patients with ascites Lars Bossen Received Received
  FRI-038 Presence of ACLF is the best predictor of mortality in patients with decompensated chronic liver disease managed in a non-specialist environment Laura Burke Received Received
  THU-038 The effect of planned care on resource use and end of life outcomes in patients with diuretic resistant ascites: a retrospective cohort study of deaths in England Benjamin Hudson Received Received
  THU-039 Human ascites microfibril-associated protein 4 is an independent predictor of mortality in decompensated cirrhosis Bjørn Stæhr Madsen Received Received
  SAT-039 HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment Tommaso Di Maira Received Received
  FRI-039 Maternal and pregnancy outcomes in women with cirrhosis: Room for optimizing care Mary Rinella Received Received
  FRI-040 Prospective study to evaluate the resolution of minimal hepatic encephalopathy after antiviral treatment in patients with HCV liver cirrhosis Marta Hernandez Conde Received Received
  SAT-040 Malnutrition is an independent predictor of immune dysfunction in cirrhotic patients Siddharth Sood Received Received
  THU-040 New International club of ascites definition of acute kidney injury applied at admission is not independently associated with mortality in patients with acute-on-chronic liver failure C Ganesh Pai Received Received
  THU-041 Hepatic hydrothorax in patients with cirrhosis and ascites – its prevalence and association with other cirrhosis complications Daniela Matei Received Received
  SAT-041 Albumin-bilirubin grade allows accurate prediction of live births in patients with liver disease Tiong Yeng Lim Received Received
  FRI-041 Rifaximin-a is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study Mark Hudson Received Received
  FRI-042 A standardized CT estimation of liver volume is associated to the severity of cirrhosis and predicts the risk of decompensation Ana Clemente Received Received
  SAT-042 Alcoholic cirrhosis is not a risk factor for acute myocardial infarction: a nationwide cohort study Thomas Deleuran Received Received
  THU-042 Proton pump inhibitors increase the risk for hepatic encephalopathy in patients with cirrhosis and ascites Daniela Matei Received Received
  THU-043 Ethnic differences in overall survival of patients with cirrhosis: results of a cohort of 2939 United States patients with long-term follow-up Pauline Nguyen Received Received
  SAT-043 Sarcopenia represents a risk factor for the development of hepatic encephalopathy after transjugular intrahepatic portosysthemic shunt Silvia Nardelli Received Received
  FRI-043 Cellulitis is a common precipitant of acute kidney injury and mortality in patients with cirrhosis Luis Téllez Received Received
  FRI-044 Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study Macarena Simón-Talero Received Received
  SAT-044 Effect of spontaneous bacterial peritonitis on mortality among patients with alcoholic cirrhosis and ascites Thomas Deleuran Received Received
  THU-044 Evaluation of the CLIF-C ACLF score in critically ill cirrhotic patients in intensive care units in Europe and North America: a multicenter cohort study Constantine Jason Karvellas Received Received
  THU-045 Urinary MicroARNs as potential biomarkers to predict the evolution of kidney function after liver transplantation in patients with cirrhosis Clement Lejealle Received Received
  SAT-045 The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it? Stephen Chris Pappas Received Received
  FRI-045 Non-invasive measures to predict the presence of oesophageal varices in real life practice Mafalda Sousa Received Received
  FRI-046 GR3027 reverses neurosteroid-induced, GABAA receptor-mediated inhibition of brain function: A human challenge study Maja Johansson Received Received
  SAT-046 Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates Theresa Bucsics Received Received
  THU-046 The impact of esophageal varices on the prognosis of patients with hepatocellular carcinoma after surgical resection: A propensity score matching analysis Chung-Yu Chang Received Received
  THU-047 Not all of the patients with hepatitis B-related hepatocellular carcinoma require endoscopic screening for esophageal varices: a large cohort study Chung-Yu Chang Received Received
  FRI-047 Changes in the model for end-stage liver disease (MELD) scores on day 7 predict mortality in acute on chronic liver disease: the delta-MELD project Majd B Protty Received Received
  SAT-047 Efficacy of nutritional therapy on quality of life in liver cirrhosis with minimal hepatic encephalopathy- randomized controlled trial Sudhir Maharshi Received Received
  FRI-048 Effect of terlipressin treatment in liver transplant-eligible patients with hepatorenal syndrome Marc Nguyen-Tat Received Received
  THU-048 End-stage cirrhotic patients rarely receive adequate palliative care. Can we do something earlier? Chun-Han Cheng Received Received
  SAT-048 The National Early Warning Score accurately discriminates the risk of serious in-hospital adverse outcomes in patients with liver disease Therasa J. Hydes Received Received
  THU-049 External validation of a new equation predicting glomerular filtration rate in patients with cirrhosis candidates for liver transplantation and impaired renal function Claire Francoz Received Received
  SAT-049 Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites Tammo Lambert Tergast Received Received
  FRI-049 Prevalence and clinical implications of hemophagocytic syndrome in patients with infection-induced acute on chronic liver failure – a retrospective pilot study Mariana Verdelho Machado Received Received
  FRI-050 The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses Marcus Maximilian Mücke Received Received
  SAT-050 Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites Tammo Lambert Tergast Received Received
  SAT-051 Erythropoietin treatment reduces inflammatory reaction and improves liver regeneration after major hepatic resection in cirrhotic rat models Sukwon Suh Received Received
  FRI-051 Abnormalities in skin temperature and its 24-hour rhythm in patients with cirrhosis: sleep-wake and general clinical implications Maria Garrido Received Received
  FRI-053 Glutamine synthetase in endothelial cells of the blood-brain barrier: less but not insignificant? Mariana M Oliveira Received Received
  SAT-053 The alternate renin angiotensin system is upregulated and Ang-(1-7) mediates vasodilatation in human cirrhosis Stephen Casey Received Received
  SAT-054 PTTG1/DLK1, a new signaling pathway involved in the pathogenesis of liver fibrosis Silvia Carvajal Received Received
  THU-054 TGR5 plays a protective role against portal hypertension in LCA induced liver damage in mice Caroline Klindt Received Received
  FRI-054 Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities Louise China Received Received
  FRI-055 Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions Louise China Received Received
  THU-055 Minimal hepatic encephalopathy is associated with increased capacity to eliminate superoxide and peroxynitrite in lymphocytes Carmina Montoliu Received Received
  SAT-055 Decreased levels of crucial complement pathway components in patients with advanced liver cirrhosis Signe Glargaard Received Received
  SAT-056 Collapsed reticular network during the initiation and progression of hepatic fibrosis in rat and human livers Shi-Lei Wen Received Received
  THU-056 Extracellular matrix turnover is regulated in 3D disease-specific human liver scaffolds engineered with human hepatic stellate cells Diana Julie Leeming Received Received
  FRI-056 Survival predictors in cirrhotic patients with refractory ascites treated with transjugular intrahepatic portosystemic shunt Marta Aicart-Ramos Received Received
  FRI-057 Intestinal inflammation worsens epithelial barrier function in rats with cirrhosis and ascites: role of commensal gut flora Agustín Albillos Received Received
  THU-057 Low sensitivity to thrombomodulin in patients with cirrhosis; Impact of factor VIII increase and protein C deficiency Armand Abergel Received Received
  SAT-057 Toll-like receptor polymorphisms compromise the inflammatory response against translocated bacterial antigens in cirrhosis Paula Piñero Romero Received Received
  SAT-058 Thyroid Hormone receptor regulates hepatic stellate cell activation Paul P. Manka Received Received
  THU-058 Genetic determinants influencing on overt hepatic encephalopathy and acute-on-chronic liver failure Antonio Gil-Gómez Received Received
  FRI-058 Cannabinoid receptor 1 mediates M1 polarization of bone marrow-derived monocytes/macrophages via RhoA/NF-?B p65 and ERK1/2 signaling pathways respectively in mouse fibrotic liver Le Yang Received Received
  FRI-059 Beneficial effects of octrotide on intrahepatic angiogenesis via somatostatin receptor 2 in portal hypertensive and cirrhotic rats Jinhang Gao Received Received
  THU-059 Impaired cerebral oxygenation, but preserved cerebrovascular reactivity, in an animal model of hepatic encephalopathy Anna Hadjihambi Received Received
  SAT-059 B. pseudocatenulatum CECT7765 effect on intestinal microbiota of rats with bile duct ligation Oriol Juanola Juárez Received Received
  THU-060 Brain glymphatic clearance is impaired in a rat model of cirrhosis Anna Hadjihambi Received Received
  SAT-060 Treatment with anti-TNFa reduces neuroinflammation and restores neurotransmission, learning and motor coordination in rats with hepatic encephalopathy Vicente Felipo Received Received
  THU-061 Progression of cirrhotic liver disease towards acute-on-chronic liver failure triggers changes in innate immune cell phenotype and their response to pro-inflammatory stimuli Alexander AN Maini Received Received
  SAT-062 New animal model of obesity and chronic liver disease to provide insights on non-alcoholic liver disease-induced hepatic encephalopathy Ochoa-Sanchez Rafael Received Received
  FRI-062 Functional cortical connectivity is disturbed in patients with cirrhosis even when neuropsychometric performance is unimpaired Harry D Zacharias Received Received
  THU-062 Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis Alessandra Brocca Received Received
  FRI-063 Inhibition of macrophage infiltrations by thalidomide improves muscle wasting of cirrhotic rats Han-Chieh Lin Received Received
  SAT-063 Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis Vincenzo La Mura Received Received
  THU-063 A novel population of immunosuppressive CD8 T cells is expanded in patients with decompensated liver disease Fanny Lebosse Received Received
  THU-064 Simvastatin neither reduces gut bacterial translocation nor sistemic/mesenteric inflammation in cirrhotic rats with ascites Agustín Albillos Received Received
  SAT-064 Effects of melatonin in hepatopulmonary syndrome induced biliar duct ligation in rats Norma Possa Marroni Received Received
  SAT-065 Protective effect of melatonin on carbon tetrachloride-induced chronic hepatotoxicity Norma Possa Marroni Received Received
  FRI-065 Activation of proinflammatory citokines is involved in muscle wasting in mice model of carbon tetrachloride induced liver cirrhosis Michela Giusto Received Received
  THU-065 Osteoprotegerin production and profibrotic activity in liver fibrosis are TGFß dependent Adhyatmika Adhyatmika Received Received
  THU-066 Osteoprotegerin is more than a serum marker in liver fibrosis Adhyatmika Adhyatmika Received Received
  FRI-066 Vascular morphology alterations during liver cirrhogenesis in rats Geert Peeters Received Received
  FRI-067 Impact of sustained virological response to interferon therapy for chronic hepatitis C on recurrence and long-term survival in patients with hepatocellular carcinoma Hiroji Shinkawa Received Received
  SAT-067 Regulation of the NLRP3 inflammasome in monocytes and macrophages from patients with decompensated cirrhosis by low-dose genotoxic stress Nilay Koese Received Received
  THU-068 Trunk and branch drivers in hepatocellular carcinoma: impact of molecular heterogeneity Agrin Moeini Received Received
  SAT-068 Elevated levels of circulating osteopontin in patients with cholangiocarcinoma predict poor survival after tumor resection Sven H. Loosen Received Received
  THU-069 The systemic inflammatory response is a prognostic marker in human immunodeficiency virus-infected patients with hepatocellular carcinoma David James Pinato Received Received
  SAT-069 Pathomolecular scoring and diagnostic algorithm of atypical hepatocellular adenomas: a clue for malignant transformation Valérie Paradis Received Received
  SAT-070 Serum Wisteria Floribunda agglutinin-positive sialylated mucin 1 as a biomarker of hepatic progenitor cell/biliary features in hepatocellular carcinoma and of recurrence after curative therapy Nobuharu Tamaki Received Received
  FRI-070 Development of de novo and recurrent hepatocellular carcinoma in a Romanian cohort of compensated HCV genotype 1b liver cirrhosis with SVR after 3D and ribavirin therapy Liana Gheorghe Received Received
  THU-070 Rising incidence of hepatocellular carcinoma in a Spanish health area between 2008 and 2016 Alberto Lue´ Received Received
  THU-071 Laparoscopic ablation for hepatocellular carcinoma: proposal of a 6-months mortality score for patient selection based on more than 1000 procedures Alessandro Vitale Received Received
  FRI-071 Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver Hyo Jung Cho Received Received
  SAT-071 ASS1 immunohistochemistry identifies unclassified hepatocellular adenoma. Experience of a single French liver center Paulette Bioulac-Sage Received Received
  SAT-072 Higher rates of cirrhosis, decompensation, and hepatocellular carcinoma (HCC) in Asian and Hispanic patients with Hepatitis C (HCV) Infection compared to White and Black ethnicity regardless of gender differences: a single center study in the U.S. Pauline Nguyen Received Received
  THU-072 Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence Alvaro Diaz-Gonzalez Received Received
  THU-073 Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma Devalingam Mahalingam Received Received
  SAT-073 The prognosis of single large hepatocellular carcinoma was distinct from the BCLC stage A or B Pei-Chang Lee Received Received
  FRI-074 Determinants of long term survival and recurrence patterns after radiofrequency ablation for hepatocellular carcinoma developed on cirrhosis Manon Allaire Received Received
  SAT-074 Validation of novel eligibility criteria by integrating ALBI grade and progression pattern for sorafenib-failed hepatocellular carcinoma Pei-Chang Lee Received Received
  FRI-075 Conditional probability of long-term survival in patients with locally advanced and metastatic hilar cholangiocarcinoma Marcia Gaspersz Received Received
  SAT-075 The long-term outcomes of patients with the Barcelona Clinic Liver Cancer stage 0 hepatocellular carcinoma after radiofrequency ablation therapy Pei-Chang Lee Received Received
  THU-075 Albumin-Bilirubin grade based novel risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization Dong Hyun Sinn Received Received
  THU-076 CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules Fabio Piscaglia Received Received
  SAT-076 Polymorphisms in the cyclooxygenase-2 (COX-2) gene, vascular endothelial growth factor (VEGF) and methylenetetrahydrofolate reductase (MTHFR) gene in patients with hepatocellular carcinoma and hepatitis C virus infection Sylene Coutinho Rampche de Carvalho Received Received
  FRI-076 The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma Marcia Gaspersz Received Received
  FRI-077 Black hepatocellular carcinoma patients diagnosed after 2010 have worse long-term survival than white patients Jacqueline Estevez Received Received
  SAT-077 Relationship between overall survival and time to progression after transarterial chemoembolization therapy in patients with hepatocellular carcinoma Tadaaki Arizumi Received Received
  THU-077 Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals Andres Castaño Received Received
  FRI-078 Temporary suspension of sorafenib by adverse effects is associated with longer survival in patients with hepatocellular carcinoma Maria Varela Received Received
  SAT-078 Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study Philip Broadhurst Received Received
  SAT-079 Serum biomarker (´GALAD´) response after resection of hepatocellular carcinoma: impact of tumour recurrence Philip J Johnson Received Received
  THU-079 Advanced BCLC hepatocellular carcinoma includes a very heterogeneous patient population treatable with different therapies and with different prognosis Francesca Garuti Received Received
  FRI-079 Functional health literacy can affect patient perception for the need for liver imaging for HCC screening Jasmohan Singh Bajaj Received Received
  THU-080 Serum microRNAs as biomarkers for cirrhosis and hepatocellular carcinoma in Hepatitis C Anna Weis Received Received
  SAT-080 Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a european multicentric study Philippe Kolly Received Received
  FRI-080 Telomerase activity: a valuable marker of hepatocelluar carcinoma development in cirrhotic hepatitis C patients Nihal Mohamed El-Habachi Received Received
  FRI-081 Identification of actionable mutations in circulating cell-free tumour DNA as a prognostic biomarker in hepatocellular carcinoma Jessica Howell Received Received
  THU-081 Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis Friederike Mettke Received Received
  THU-082 Resection of larger hepatocellular adenomas: when is it justified? Anne Julia Klompenhouwer Received Received
  FRI-082 The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma Ji Hye Seo Received Received
  SAT-082 The diagnostic and prognostic values of serum PIVKA-II in Thai patients with hepatitis B-related hepatocellular carcinoma Pisit Tangkijvanich Received Received
  SAT-083 Adjuvant Huaier granule for hepatocellular carcinoma after curative resection: A phase IV, multicenter, randomized, and parallel-group controlled clinical trial Qian Chen Received Received
  FRI-083 Prognostic significance of co-expression of programmed cell death 1 and its ligand 1 in resectable hepatocellular carcinoma Jihyun An Received Received
  FRI-084 Combined Effect of Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and Programmed Cell Death 1 Ligand 1 (PD-L1) expression in tumor infiltrating lymphocytes on prognostic outcomes after resection of hepatocellular carcinoma Jihyun An Received Received
  SAT-084 Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy Ramy Ibrahim Kamal Jouness Received Received
  THU-084 Predictors for successful downstaging in patients with BCLC intermediate stage hepatocellular carcinoma Annelotte Broekhoven Received Received
  FRI-085 Neuroligin4 over expression on natural killer cells cause their impairment in patients with cirrhosis and hepatocellular carcinoma Johnny Amer Received Received
  THU-085 Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or antagonist II Gian Paolo Caviglia Received Received
  SAT-085 Significantly lower rates of cirrhosis and worse long-term survival in cryptogenic hepatocellular carcinoma compared to viral etiologies: results of a multi-center international cohort Tomi Jun Received Received
  THU-086 The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients Giovanni Marasco Received Received
  SAT-086 The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience Rob Bielen Received Received
  FRI-086 Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma Martha M Kirstein Received Received
  THU-087 Portal vein infiltration in patients with hepatocellular carcinoma: the impact of correct classification Arndt Weinmann Received Received
  SAT-087 Significance of serum exosomal miR-122 and miR-21 as a predictive biomarker in hepatocellular carcinoma patients who underwent transarterial chemoembolization Tomoyuki Suehiro Received Received
  SAT-088 Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma Rocco Granata Received Received
  THU-088 Management of people with early or very early stage hepatocellular carcinoma: an attempted network meta-analysis Avik Majumdar Received Received
  SAT-089 A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin Torsten Voigtländer Received Received
  FRI-089 Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: a single-centre experience after 54 treatments Martha M Kirstein Received Received
  THU-089 The effect of antiviral treatment on hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma Gab Jin Cheon Received Received
  SAT-090 Extent of portal invasion in patients with hepatocellular carcinoma: the more, the worse? Roman Kloeckner Received Received
  THU-090 Operability of perihilar cholangiocellular carcinoma can be reliably predicted by combination of endoscopic retrograde cholangiography, endoscopic ultrasound and computer tomography as variables in the European staging system Bernhard Schlevogt Received Received
  FRI-090 Improved prediction of survival by a risk factor-integrated inflammatory score in Sorafenib treated hepatocellular carcinoma Martin Franz Sprinzl Received Received
  SAT-091 Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis Wolfgang Mikulits Received Received
  FRI-091 Novel circulating cell free DNA methylation alterations as a biomarker for the detection of hepatocellular carcinoma Ju Dong Yang Received Received
  FRI-092 Validation of the ALBI grade as a substitute for the Child-Pugh class in the BCLC classification of hepatocellular carcinoma and of the additional value provided by the Neutrophil-to-Lymphocyte Ratio Matteo Colombo Received Received
  THU-092 Alpha-fetoprotein levels before and after sustained virological response with direct- acting antivirals in patients with liver cirrhosis due to hepatitis C virus Carmen Alvarez-Navascues Received Received
  SAT-092 Circulating tumour-associated microparticles in liver cancer: a question of tumour diameter and volume? Sabine Katharina Urban Received Received
  SAT-093 Characteristics of conversion to 2nd line treatment in sorafenib-treated advanced hepatocellular carcinoma patients Sadahisa Ogasawara Received Received
  FRI-093 The optimal cutoff value of serum alpha-fetoprotein in the diagnosis of hepatocellular carcinoma Jung-Fa Tsai Received Received
  FRI-094 External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study Mauro Borzio Received Received
  SAT-094 Impact of survival after moving onto the end-of-life care in patients with hepatocellular carcinoma Sadahisa Ogasawara Received Received
  SAT-095 The expression of SALL4 and its clinical significance in hepatocellular carcinoma Xiaoyu Wen Received Received
  THU-095 Clinical features of hepatocellular carcinoma in the elderly in a hepatitis B endemic country - a comparative study of 1430 cases Chang-Chuen Mark Cheah Received Received
  FRI-095 Previous and resolved hepatitis B virus infection is not a risk factor for the development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus or alcohol Carlos Rodríguez-Escaja Received Received
  SAT-096 Sorafenib therapy in orthotopic liver transplant recipients with hepatocellular carcinoma beyond Milan criteria on explant Sanjaya Kumar Satapathy Received Received
  THU-096 Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals Giuseppe Cabibbo Received Received
  FRI-096 Short-Course carbon-ion radiation therapy for hepatocellular carcinoma: a nationwide survey by Japan Carbon Ion Radiation Oncology Study Group (J-CROS 1504) Kei Shibuya Received Received
  FRI-097 Treatment patterns and clinical outcomes for patients with hepatocellular carcinoma from China: a sub-analysis of the Global Hepatocellular Carcinoma BRIDGE Study Minshan Chen Received Received
  SAT-097 Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology Sarah Berhane Received Received
  THU-097 Hepatocellular carcinoma and rheumatoid arthritis: a 10-year population-based propensity-score matched cohort study in Taiwan Ching-Sheng Hsu Received Received
  SAT-098 Clinicopathological characteristics of Intrahepatic sarcomatoid cholangiocarcinoma: 11 cases in single center experience Yang-Hyon Baek Received Received
  FRI-098 Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma Nadine Abi-Jaoudeh Received Received
  THU-098 Transarterial chemoembolizaton combined with sorafenib for intermediate-stage hepatocellular carcinoma: a window of tumor burden for survival benefit Guohong Han Received Received
  THU-099 The malignant transformation of hepatocellular adenoma: experience of a French liver center Christine Sempoux Received Received
  FRI-099 PET/CT findings using 18F-labeled galactose tracer (FDGal) vs. 18F-labeled glucose tracer (FDG) in patients with hepatocellular carcinoma Kirstine Petrea Bak-Fredslund Received Received
  SAT-099 Utility of serum alpha-fetoprotein measurement with a cutoff of 20ng/mL in addition to ultrasound surveillance for hepatocellular carcinoma in patients with chronic hepatitis B - a regression discontinuity analysis Yan-Zheng Daniel Lim Received Received
  FRI-100 EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk Kornelius Schulze Received Received
  THU-100 Radiological assessments in patients with hepatocellular carcinoma following transarterial chemoembolization: can initial response independently predict the survival regardless of tumor load? Guohong Han Received Received
  THU-101 Hepatocellular carcinoma diagnostic performance of liver imaging reporting and data system for contrast enhanced ultrasound and of quantitative contrast enhanced ultrasound Cosmin Gabriel Cristea Received Received
  FRI-101 Analysis of the breath metabolome in patients with Hepatocellular carcinoma Ghassoub Rifai Received Received
  SAT-101 Plasma micoRNA-21, 26a, and 29a-3p as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma Soon Sun Kim Received Received
  SAT-102 A low incidence of hepatocellular carcinoma in patients with genotype 1b compensated cirrhosis treated with paritaprevir/ritonavir, ombitasvir and dasabuvir ± ribavirin in a tertiary center: a matter of better selection? Stefan Chiriac Received Received
  THU-102 Plasma microvesicles levels can predict the development of hepatocellular carcinoma in patients with cirrhosis Cristina Levi Received Received
  FRI-102 Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology Ming-Lung Yu Received Received
  THU-103 Hand-foot-skin reaction of grade two or higher within sixty days as the best response criterion for survival prediction in hepatocellular carcinoma treated by sorafenib Guohong Han Received Received
  FRI-103 Temporal trends in etiology of liver disease, tumor characteristics, and long-term survival of patients with hepatocellular carcinoma: results of a single-center U.S. cohort from 1997-2016 Pauline Nguyen Received Received
  SAT-103 Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib Yoshiyuki Wada Received Received
  FRI-104 Activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis Lei Ling Received Received
  SAT-104 Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience Stefano Okolicsanyi Received Received
  THU-104 Close association of arrest-defective protein 1 (ARD1) overexpression with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma Danbi Lee Received Received
  SAT-105 Hepatocellular carcinoma in elderly patients referred to a tertiary center with multidisciplinary team approach: clinical presentation and outcomes Stefano Okolicsanyi Received Received
  SAT-106 Early changes in perfusion-computed tomography scan parameters as a marker of improved outcomes in patients with hepatocellular carcinoma treated with Sorafenib Stefano Okolicsanyi Received Received
  FRI-106 Effect of novel AKT inhibitor ARQ 751 as single agent and its combination with sorafenib on hepatocellular carcinoma in a cirrhotic rat model Kurma Keerthi Received Received
  FRI-107 Kangai 1 C-terminal interacting tetraspanin plays an important role in cholangiocarcinogenesis Khac Cuong Bui Received Received
  THU-107 Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study David James Pinato Received Received
  FRI-108 RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses Keun Soo Ahn Received Received
  SAT-108 Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib Yutaka Yasui Received Received
  THU-108 CRIPTO expression in hepatocellular carcinoma Danny van der Helm Received Received
  SAT-109 Identification of tumour suppressive and oncogenic microRNAs in gallbladder carcinoma Stephanie Roessler Received Received
  FRI-109 PNPLA3 p.I148M risk allele carriers might be at-risk of chemotherapy- associated steatohepatitis (CASH) Marcin Krawczyk Received Received
  THU-109 Intra-tumour heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma David James Pinato Received Received
  FRI-110 Targeting tumour-stromal interactions – differential pharmacological modification of AMPK/mTORC1 in human hepatic stellate cells and hepatocellular carcinoma Katrin Schölzel Received Received
  SAT-110 Kupffer cells as antigen-presenting cells in mouse livers with hepatocellular carcinoma Stephanie Lacotte Received Received
  SAT-111 Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1alpha-related release of VEGF-A Stefania Cannito Received Received
  FRI-111 IMPDH exerts a tumor-suppressing role in hepatocellular carcinoma Kan Chen Received Received
  THU-111 DPP4 inhibition reveals interleukin-33–dependent eosinophil-mediated tumor immunity in hepatocellular carcinoma Clémence Hollande Received Received
  FRI-112 Hepatocyte nanodelivery using siRNA c-Jun N-terminal Kinase-2 (siJnk2) for the treatment of chronic liver disease Marius Maximilian Woitok Received Received
  SAT-113 Impact of natural killer cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients Simona Onali Received Received
  THU-113 Role of RAS-dependent signaling pathways in hepatic carcinogenesis Christian Lechler Received Received
  FRI-113 Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification Julien Calderaro Received Received
  THU-114 Hepatic tumour burden is reduced by endogenous overexpression of chemerin-157 Elisabeth Margareta Haberl Received Received
  SAT-115 Fatty liver binding protein 4: a targetable adipokine in hepatocellular carcinoma related to metabolic syndrome Samira Laouirem Received Received
  FRI-115 Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma Jose J.G. Marin Received Received
  THU-115 Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma Eric Robinet Received Received
  SAT-116 Metformin reduces cell migration and down-regulates epithelial to mesenchymal transition by AMPK / Foxo3a pathway in human intrahepatic cholangiocarcinoma Sabina Di Matteo Received Received
  FRI-116 IL6-dependent genomic instability Heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis Jonathan H. Axelrod Received Received
  THU-116 Inhibition of lymph node metastasis by CTGF in Notch1 driven malignant transformation of rat liver oval cells Chao Liu Received Received
  FRI-117 Insulin/IGF-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells Javier Vaquero Received Received
  SAT-117 Molecular basis of natural killer cell dysfunction in hepatocellular carcinoma Gabriele Missale Received Received
  THU-117 Tumour suppressor SH2D4A is involved in endosomal trafficking of STAT3 in hepatocellular carcinoma cells Carolin Ploeger Received Received
  FRI-118 Chromosomal aberrations are effected by transformation-related protein 53 deletion in inflammation induced hepatocarcinogenesis Michael Svinarenko Received Received
  THU-118 Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection Fukiko Kawai-Kitahata Received Received
  SAT-118 DNA circulating free in patients with hepatocellular carcinoma Valérie Dejour Received Received
  THU-119 Functional role of CCL5/RANTES for hepatocellular carcinoma progression during chronic liver disease Antje Mohs Received Received
  FRI-119 Free fatty acids enhance CD36 knockdown in primary human hepatocytes and abrogate PTEN expression – recapitulation of NASH-associated HCC Jan-Peter Sowa Received Received
  SAT-119 Fractalkine-CX3CR1 is the only predictor for mortality in hepatocellular carcinoma patients treated with curative radiofrequency ablation Wei Teng Received Received
  FRI-120 Extracellular ATP and subsequent purinergic P2Y2 receptor signalling promote liver tumorigenesis in mice Isabel Schulien Received Received
  THU-120 miR-22 deficiency fosters hepatic tumour development Anne-Sophie Ay-Berthomieu Received Received
  SAT-120 Exome sequencing identifies a mutation associated with hepatocellular carcinoma development in hepatitis C virus infected individuals Rodrigo Feliciano Carmo Received Received
  THU-121 Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management Anne-Aurelie Raymond Received Received
  FRI-121 Rapamycin and zoledronic acid synergistically repolarize tumour associated macrophages towards anti-HCC responses Misbah Aslam Received Received
  SAT-121 Identification of invasion-addicted genes driven by transforming growth factor-beta in hepatocellular carcinoma Wolfgang Mikulits Received Received
  SAT-122 Integrated analysis of exosomal microRNA, gene, and pathway regulatory networks in fibrosis and hepatocarcinogenesis Robert Cheng Received Received
  THU-122 RIPK1 suppresses a TRAF2-dependent pathway to liver cancer Tom Luedde Received Received
  SAT-123 Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers Richard Bethell Received Received
  FRI-123 Molecular characterization of the immune class of hepatocellular carcinoma Iris Martinez-Quetglas Received Received
  THU-123 A small number of senescent hepatocytes is sufficient to attenuate liver regeneration and enhance tumorigenesis Anna Potapova Received Received
  THU-124 Cerium oxide nanoparticles display anti-tumoral activity and improve survival in experimental hepatocellular carcinoma Guillermo Fernandez-Varo Received Received
  FRI-124 TGF-ß oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response Iris Martinez Quetglas Received Received
  SAT-124 VEPH1 regulates the occurrence and development of hepatocellular carcinoma by affecting the PI3K/Akt/mTOR signal pathway Pinging Dong Received Received
  FRI-125 Characterization of cancer associated fibroblasts in primary site and metaststic lymph nodes of intrahepatic cholangiocarcinoma by immunohistochmistry Naoki Uyama Received Received
  THU-125 The absence of OCT1 at the plasma membrane of tumor cells is associated with a worse response of hepatocellular carcinoma to sorafenib Johannes Weiss Received Received
  THU-126 A new in vitro hepatocellular carcinoma model based on human normal and fibrotic 3D extracellular matrix scaffold bio-engineering Andrea Telese Received Received
  FRI-126 Selenoenzyme glutathione peroxidase 4 affects profile of infiltrating immune cell in hepatocellular carcinoma Nataliya Rohr-Udilova Received Received
  SAT-126 CCL2-dependent monocyte recruitment contributes to a tumor-promoting microenvironment in a combined fibrosis-HCC model Peter Leonard Schrammen Received Received
  SAT-127 CCAAT/Enhancer Binding Protein Delta exerts tumor-supportive effects but is down-regulated in patient hepatocellular carcinoma Pengyu Liu Received Received
  FRI-127 Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib Hyo Jung Cho Received Received
  THU-127 microRNA-34a and natural killer cells: an immuno-epigenetic approach to halt hepatocellular carcinoma progression Amira Khaled Abdelhamid Received Received
  THU-128 The anti-inflammatory receptor TREM-2 protects the liver from hepatocellular carcinoma development Aitor Esparza-Baquer Received Received
  FRI-128 Overexpression of arrest-defective protein 1 in dysplastic hepatic nodule as a possible marker of malignant potential Hyo Jeong Kang Received Received
  FRI-129 Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC Nicola Coppola Received Received
  SAT-129 Distinct features of early and late-stage liver cancer cells correlate with their response to metabolic perturbation Zeribe Nwosu Received Received
  THU-129 Chronic treatment with over-the-counter H1 or H2 histamine receptor blockers decreases cholangiocarcinoma xenograft tumor growth, angiogenesis and EMT Heather Francis Received Received
  THU-130 Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice Ibrahim M. Sayed Received Received
  FRI-130 Prevalence and risk factors for hepatitis B infection in the adult population of Georgia: a nationwide survey Ana Kasradze Received Received
  FRI-131 Interferon-free antiviral therapy does not increase the risk of developing short term hepatocellular carcinoma in patients with cirrhosis infected with hepatitis C virus Andrea Nuñez Received Received
  SAT-131 AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model Zuzana Macek Jilkova Received Received
  FRI-132 Prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders Anna Parfieniuk-Kowerda Received Received
  THU-132 Common polymorphisms in the TLR3 gene are stronger associated with spontaneous clearance of Hepatitis B virus infection in caucasians than variants of the HLA gene Janett Fischer Received Received
  THU-133 Identification of serum metabolite profiles associated with the risk of developing hepatitis B-related hepatocellular carcinoma using metabolomics Jia-Kai Hsu Received Received
  FRI-133 In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? Arianna Battisti Received Received
  SAT-133 Incidence and mortality of viral hepatitis in China Mingyuan Zhang Received Received
  FRI-134 Mother-to-child transmission of hepatitis B virus in Ethiopia Asgeir Johannessen Received Received
  THU-134 Serum hepatitis B core antibody as a novel tool to assess hepatic inflammation guide antiviral decision-making in chronic hepatitis B patients with normal alanine aminotransferase levels Jiyuan Zhou Received Received
  SAT-134 Re-evaluation of chronic hepatitis B patients lost to follow-up: results from the northern holland retrieval project Nina Beekmans Received Received
  THU-135 Progesterone receptor mutations predisposes to HEV infection in the HIV-positive host Jose Daniel Debes Received Received
  FRI-135 Clinical outcomes were comparable between chronic hepatitis B patients with virological response using oral antiviral therapy and inactive carriers when adjusting for fibrotic burden Beom Kyung Kim Received Received
  SAT-136 Noninvasive models to predict liver fibrosis in patients with chronic hepatitis B: a study from Turkey Pinar Korkmaz Received Received
  THU-136 Correlation of hepatitis B virus genomic variants with HBsAg Titers and HBV-DNA levels in a large European study cohort of patients with chronic hepatitis B Kai-Henrik Peiffer Received Received
  SAT-137 Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of genotype 3: interim result of 8-month prospective follow-up study Piyawat Komolmit Received Received
  FRI-137 Association between mutations on the basal core promoter region and hepatocellular carcinoma in Vietnamese chronic hepatitis B patients Cam Huong Thi Nguyen Received Received
  THU-138 Impact of chronic liver disease on the survival of patients hospitalized with acute hepatitis A infection: nationwide hospital admission data from Thailand Kittiyod Poovorawan Received Received
  SAT-138 A five-year single centre experience of hepatitis E virus infection during pregnancy from New Delhi Premashis Kar Received Received
  FRI-138 2´-C-methylcytidine inhibits hepatitis E virus replication but antagonizing ribavirin Changbo Qu Received Received
  SAT-139 The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification Lorenzo Piermatteo Received Received
  THU-139 A nationwide seroprevalence of hepatitis a in Republic of Korea from 2005 to 2014, before and after peak outbreak in 2009 Sook-Hyang Jeong Received Received
  FRI-139 Phenotypic and genotypic shifts of hepatitis B virus in treatment naïve patients following extensive use of antivirals in a chronic hepatitis B endemic area Chau-Ting Yeh Received Received
  FRI-140 Identificaiton of an hot integration area for hepatitis B viral genome in the tenth intron of DEP Domain-Containing 5 gene in hepatoma patients with unfavorable postoperative prognosis Chau-Ting Yeh Received Received
  SAT-140 Poor adherence to hepatitis B screening protocols prior to rituximab; a multicentre South Australian study Alan Wigg Received Received
  THU-140 Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib Laurent Alric Received Received
  THU-141 The pro-inflammatory CD161+CD4+ T cells were recruited to liver through C-X-C motif chemokine receptor 6 (CXCR6)-C-X-C motif chemokine ligand 16 (CXCL16) and CX3CR1-CX3CL1 axes during chronic hepatitis B Li-Sha Cheng Received Received
  FRI-141 Increased natural killer cell function after structured interruption of long-term nucleos(t)ide analogue therapy is associated with active hepatitis Christine Lea Zimmer Received Received
  SAT-141 A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China Sze Hang Kevin Liu Received Received
  THU-142 Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA Luna Colagrossi Received Received
  THU-143 Nucleos(t)ide analogue decreased liver stiffness of e-antigen negative chronic hepatitis B (CHB) patients over a 10-year interval Lung-Yi Mak Received Received
  SAT-143 Identifying true inactive HBV carriers using fibrosis-4 index Tai-Chung Tseng Received Received
  FRI-143 Characterization and evaluation of hepatic fibrosis degree in patients with chronic hepatitis B virus infection with normal transaminases Cristina San Juan Received Received
  THU-144 Absence of hepatitis B reactivation among veterans with serological evidence of previous hepatitis B infection receiving anti-hepatitis C direct acting antivirals Lydia Tang Received Received
  SAT-144 Anti-HEV seroprevalence rate in the Americas Thomas Horvatits Received Received
  FRI-144 Frequent delayed hepatitis B surface antigen spontaneous clearance among high risk groups Daniela K van Santen Received Received
  FRI-145 The value of subtyping genotype A in chronic hepatitis B: differences in disease course and implications for therapy Enoka Gonsalkorala Received Received
  SAT-145 Further evaluation of the RoboGene Kit for HDV RNA quantification including viral load monitoring under therapy and performance in different genotypes Ute Hofmann Received Received
  THU-145 Prevalence, determinants of chronic hepatitis B infection and hepatitis B genotypes in multi-ethnic Suriname M. Sigrid. Mac Donald - Ottevanger Received Received
  THU-146 hepatitis C virus hepatitis B virus co-Infection disproportionately worsens cirrhosis, hepatic decompensation, and hepatocellular carcinoma incidence in Non-Asians as compared to Asians Pauline Nguyen Received Received
  SAT-146 Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain Valentina Svicher Received Received
  FRI-146 Liver transient elastography (Fibroscan©): performance for the absolute mortality and clinical disease progression risk evaluation in chronic hepatitis C Fatima Serejo Received Received
  SAT-147 Potential implications of detecting Hepatitis B surface antigen in asymptomatic people in an endemic community through medical camps Varun Gupta Received Received
  THU-148 Transient elastography evolution in non treated patients with chronic hepatitis B (CHB) infection Maria Luisa González-Diéguez Received Received
  SAT-148 Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate viral replication Wenshi Wang Received Received
  THU-149 Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria Martin Sebastian Bonacci Received Received
  SAT-149 A revisit of anti-HBc IgM in the differentiation of acute HBV infection from chronic HBV infection with acute flare-up Yi-Cheng Chen Received Received
  SAT-150 Development and validation of a simple score to select HBV-infected patients for antiviral therapy in Africa Yusuke Shimakawa Received Received
  FRI-150 Tenofovir, entecariv and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B Jung Gil Park Received Received
  THU-150 Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus Mauricio Lisker-Melman Received Received
  SAT-151 Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS) Zobair M Younossi Received Received
  THU-151 Validation of the PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir Mi Na Kim Received Received
  THU-152 Outcome in chronic hepatitis delta: differences between African and non-African patients Ivana Carey Received Received
  SAT-152 PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B Nina Le Bert Received Received
  FRI-152 No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 Angela LAM Received Received
  THU-153 Serum cholinesterase: A predictive biomarker of hepatic reserves in patients with chronic Hepatitis D Z Abbas Received Received
  THU-154 Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection Andrew Vaillant Received Received
  FRI-154 Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620 Lauke Boeijen Received Received
  SAT-154 Characterization of hepatitis delta infection in Israel: prevalence and genotypes Orna Mor Received Received
  FRI-155 An algorythm including quantitave HBsAg and HBcrAg is useful for discrimation between hepatitis B virus inactive carriers and patients with active chronic hepatitis B HBeAg negative Mar Riveiro Barciela Received Received
  THU-155 Absence of mutations in the HBsAg "a" determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol Andrew Vaillant Received Received
  SAT-155 A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B Patricia Mendez Received Received
  THU-156 Post-entry antiviral effects of nucleic acid polymers against hepatitis B virus infection in vitro Andrew Vaillant Received Received
  SAT-156 High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients Pietro Lampertico Received Received
  SAT-157 Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients Pietro Lampertico Received Received
  FRI-158 Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection Meifang Han Received Received
  THU-158 A novel mid-scale screening assay to identify compounds with anti-HDV activity Bettina Buchmann Received Received
  FRI-159 Baseline serum WFA+-M2BP level is a strong predictor of response to pegylated interferon-a in HBeAg-positive chronic hepatitis B patients Mingyu Zhu Received Received
  SAT-159 Kinetics of serum HBsAg and HBcrAg in predicting response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B Pisit Tangkijvanich Received Received
  FRI-160 Next generation sequencing identifies baseline HBV mutants associated with treatment response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B Natthaya Chuaypen Received Received
  THU-160 Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: the roles of antiHBc/antiHBs quantification Chiun Hsu Received Received
  FRI-161 Quantification of serum hepatitis B core-related antigen to understanding the hepatitis B virus and hepatitis D virus chronic infection Alicia Ruiz-Ripa Received Received
  FRI-162 PreS1/PreS2/S and precore/core mutations related with major risk of hepatocellular carcinoma in patients with "grey-zone" chronic hepatitis B Ana Isabel Gil Received Received
  THU-162 On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB Darren Wong Received Received
  THU-163 On-treatment ALT flares are associated with HBsAg loss in genotype A chronic hepatitis B-infected patients treated with nucleotide analogue therapy Darren Wong Received Received
  FRI-163 Increased hepatitis B virus (HBV) specific IFN- ? and IL17A secretion by T cell subsets in HBV infected non transmitting mothers and their HBV negative new-borns: A Novel mechanism for prevention of HBV vertical transmission Nirupma Trehanpati Received Received
  SAT-164 Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B Seng Liem Received Received
  THU-164 Superior suppression of hepatitis B virus DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-directed RNA interference agent, is coupled with standard of care drugs David Suhy Received Received
  THU-165 Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss in entecavir-suppressed CHB patients (the Endeavor study): an interim analysis Di Wu Received Received
  SAT-165 Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688 Simon P. Fletcher Received Received
  FRI-165 A new HDV mouse model showing important features of human infection and identifying MAVS as a key player in IFN-ß induction Carla Usai Received Received
  FRI-166 Hepatitis B virus quasispecies complexity is lower in hepatitis B virus–hepatitis D virus infection than in hepatitis B virus monoinfection Cristina Godoy Received Received
  SAT-166 Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hepatitis B So Young Kwon Received Received
  THU-166 Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B Pietro Lampertico Received Received
  SAT-167 Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B Steffen Wildum Received Received
  FRI-167 Identification of hepatitis B X protein regions responsible for the regulation of HBV transcription via histone modification Danny Ka Ho Wong Received Received
  FRI-168 Proteomic profiling of plasma proteins associated with spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B Fen Liu Received Received
  SAT-168 In vitro and in vivo characterization of the selective toll-like receptor 8 agonist GS-9688 Stephane Daffis Received Received
  THU-169 Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology Gian Paolo Caviglia Received Received
  SAT-170 Hepatic steatosis via controlled attenuation parameter measurements and diabetes contribute to persistent liver fibrosis in the era of long-term nucleoside analogue therapy for chronic hepatitis B Wai-Kay Seto Received Received
  FRI-170 The NLRP3 inflammasome is activated in liver tissue of patients with newly diagnosed chronic hepatitis B virus infection Georgios Germanidis Received Received
  FRI-171 Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy Gunnar Lewon Lutterkort Received Received
  SAT-172 Predictors for clinical relapse within 2 year off-ETV therapy in HBeAg negative chronic hepatitis B patients Wen-Juei Jeng Received Received
  THU-172 Experiences from one of the largest treatment programs for chronic hepatitis B in sub-Saharan Africa Hailemichael Desalegn Received Received
  FRI-172 Prediction for the incidence of hepatocellular carcinoma in patients with chronic hepatitis B after administration of nucleos(t)side analog Hideaki Takahashi Received Received
  FRI-173 Relationship between HBsAg, HBV DNA, covalently closed circular DNA and fibrosis stage in chronic HBV (HBeAg-negative) patients Konstantin Kozlov Received Received
  THU-173 Nucleic acid polymer REP2139 monotherapy reveals a short half-life of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients Andrew Vaillant Received Received
  SAT-173 Revisit HBsAg for HBeAg-negative chronic hepatitis B undergoing peginterferon treatment: a multicenter pooled-analysis study Yin Chen Wang Received Received
  SAT-174 Reduced hepatitis B and D viral entry using novel clinically-applied inhibitors of the sodium taurocholate co-transporting polypeptide Joanne Donkers Received Received
  FRI-175 High rate of progression to cirrhosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver (FL) Jie Li Received Received
  THU-175 Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study Hong Ren Received Received
  SAT-175 Comparison of HDV mono-infection with genotype 1 and 3 in CRPISPR/Cas generated humanized NTCP mice and human liver chimeric mice Katja Giersch Received Received
  FRI-176 Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study Evan Brian Cunningham Received Received
  SAT-176 Serum HBV pgRNA can serve as clinical marker for cccDNA activity in patients with HBV mono and HBV/HDV co-infection Lena Allweiss Received Received
  THU-176 A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population James Hamilton Received Received
  SAT-177 An early step of Hepatitis B virus infection is dependent on the nuclear receptor for bile acids, farnesoid X receptor alpha Patrice Andre Received Received
  FRI-177 Community pop-up clinic: a harm reduction strategy to engage hepatitis C virus infected injection drug users Ghazaleh Kiani Received Received
  FRI-178 Evaluation of a sequence-based method for hepatitis C genotyping (Deepchek SingleRound PCR and NS5B/5´UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA) Greet Boland Received Received
  SAT-179 Hepatitis B Virus infection alters the transcriptional regulation of FXR-dependent microRNAs Philipp Fritze Received Received
  THU-179 Enhancing detection and treatment of chronic hepatitis C related liver disease in vulnerable adults through a dedicated homeless hostel-based liver service: Vulnerable Adults LIver Disease Study Ahmed Hashim Received Received
  FRI-179 Integrated healthcare system implementation of one time hepatitis C virus testing for patients born between 1945 and 1965 with linkage to care James M Levin Received Received
  THU-180 Change in the trajectory of MELD scores in liver transplant candidates with hepatitis c in the direct acting antiviral era Allison Kwong Received Received
  FRI-180 Late presentation of patients with chronic hepatitis C Janne Fuglsang Hansen Received Received
  SAT-180 CRV431 and CMX157: Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug Robert Thomas Foster Received Received
  SAT-181 The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication Robert Thomas Foster Received Received
  FRI-181 A behavioral Intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial Jeffrey J Weiss Received Received
  THU-181 Interferon lambda 4 CC host genetic variant is linked with spontaneous hepatitis C virus clearance for genotypes 1, 2, and 3 Anders Widell Received Received
  SAT-182 Hepatitis B virus X RNA is present in cell culture-derived virus preparations and plasma from chronically infected patients Rudolf Beran Received Received
  FRI-182 Linkage to care of HBsAg and anti-HCV positive patients after a systematic screening approach in the German primary care setting Johannes Wiegand Received Received
  THU-182 Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: A population-based survey Antonio Massimo Ippolito Received Received
  SAT-183 Hepatic expression of oncogenes Bmi1 and Dkk1 can be induced by treatment with Hepatitis B virus particles or Lipopolysaccharide in vitro and is up-regulated in liver biopsies of patients with chronic HBV infection Ruth Broering Received Received
  FRI-183 Population level outcomes and cost-effectiveness of expanding guidance for age-based hepatitis C testing in the United States Joshua A Barocas Received Received
  THU-183 Aerobic exercise and physical activity interventions in the management of hepatic manifestations of chronic hepatitis C; a systematic review Ann Marie Monaghan Received Received
  THU-184 An assessment of physical activity levels and cardiorespiratory fitness in individuals living with hepatitis C Ann Marie Monaghan Received Received
  FRI-184 CHESS - curing hepatitis C: effect on the endothelium and cardiovascular risk Joshua S Davis Received Received
  SAT-184 Insulin enhances HBV replication and interferes with antiviral activity of IFN-a Sandra Marie-Ange Phillips Received Received
  SAT-185 Early function modulation and reprogramming of Kupffer cells promote establishment and maintenance of HBV infection Suzanne Faure-Dupuy Received Received
  THU-185 High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment Joseph S Doyle Received Received
  THU-186 Expression of NK cell receptors in childhood malignancy survivours in children with chronic hepatitis C Anna Mania Received Received
  SAT-186 Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the "grey-zone" viral load cohort Valentina Svicher Received Received
  FRI-186 Treatment of chronic hepatitis C virus (HCV) infections with direct acting antivirals in the New Mexico state prison system using the project ECHO model Karla Thornton Received Received
  THU-187 Low hepatitis C virus prevalence among human immunodeficiency virus+ individuals in Sub-Saharan Africa Anne Loarec Received Received
  SAT-187 Hepatitis B virus production is enhanced through early autophagic flux but degraded through autophagosome-lysosome fusion Yong Lin Received Received
  FRI-188 IL6-174GG genotype is associated with diabetes mellitus type 2 in patients with chronic hepatitis C Luciana Diniz Diniz Silva Received Received
  THU-188 Hepatitis B testing in a large cohort of U.S. hepatitis C virus -infected patients Anne C Moorman Received Received
  SAT-188 impact of long-term tenofovir disoproxil fumarate treatment on bone metabolism and skeletal muscle function in mouse Yu-Xuan Luo Received Received
  SAT-189 The e antigen of the Hepatitis B virus enables evasion of Type 1 Interferon immune response Zina Valaydon Received Received
  FRI-189 Muscle mass is a protector factor against low bone mineral density in hepatitis C Luciana Diniz Silva Received Received
  THU-189 An audit of hepatitis C screening and referral patterns to a specialist hepatology service in a secondary care facility in the UK Anthony Pratt Received Received
  FRI-190 Long-term fibrosis improvement after sustained virologic response in patients with chronic hepatitis C and advanced fibrosis or cirrhosis - pre-treatment cirrhosis, older age and high body mass index increases the risk for persisting fibrosis Magnus Hedenstierna Received Received
  SAT-190 Determinants of the future burden of hepatocellular carcinoma after eradication of hepatitis C virus among cirrhotic patients Prowpanga Udompap Received Received
  THU-190 Prevalence of hepatitis C in the spanish population. the prevhep study (ethon cohort) Antonio Cuadrado Lavin Received Received
  THU-191 High incidence of persistently altered liver tests after sustained virological response with direct-acting antiviral in hepatitis C monoinfected and HIV-coinfected patients Antonio Olveira Received Received
  SAT-191 The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients Rachna Shridhar Received Received
  FRI-191 Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response Marc Puigvehí Received Received
  FRI-192 An approach to hepatitis C Virus epidemiology: analysis in 7602 patients of orthopaedic surgery Maria Pipa-Muniz Received Received
  SAT-192 Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV Zeinab Abdellatif Received Received
  FRI-193 A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit Marianne Byrne Received Received
  THU-193 HCV-infected people who inject drugs (PWID): engagement in care and treatment, and prevention of reinfection Arshia Alimohammadi Received Received
  FRI-194 DAA treatment scale-up in HIV/HCV co-infection: Characterisinga population at risk for reinfection Marianne Martinello Received Received
  SAT-194 Low rates of hepatitis C virus (HCV) testing and HCV awareness among individuals at high risk for chronic HCV infection among an underserved safety-net population Robert Wong Received Received
  THU-194 Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: results of an interim analysis Astrid Marot Received Received
  FRI-195 Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals? Marjolein Van Tilborg Received Received
  THU-195 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: The SToP-C study Behzad Hajarizadeh Received Received
  SAT-195 Impact of cryoglobulinemia on HCV viral load measurements of different molecular diagnostic systems Gian Maria Prati Received Received
  FRI-196 Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions? Marjolein Van Tilborg Received Received
  SAT-196 Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4) Saeed M. El-Nahaas Received Received
  THU-196 Injecting heroin - how long until hepatitis C infection obtained? Brian Stephens Received Received
  FRI-197 Association between improved liver function and selenium depends on C718T polymorphism in 3´- untranslated region of glutathione peroxidase 4 and in humans Nataliya Rohr-Udilova Received Received
  SAT-197 Abnormal microvasculature in chronic viral hepatitis Samantha Sarcognato Received Received
  FRI-198 The impact of sustained virological response on long term risk of decompensated cirrhosis: the BC hepatitis testers cohort Naveed Z. Janjua Received Received
  THU-198 Cross-sectional assessment of >20,000 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US Jacqueline Reeves Received Received
  THU-199 The number of small low-density lipoprotein particles is decreased by hepatitis C virus G1b infection Chika Kinoshita Received Received
  FRI-199 Abbott HCV core Ag and HCV RNA comparison study in country of Georgia Nazibrola Chitadze Received Received
  SAT-199 Predictors of minimal hepatic encephalopathy in asymptomatic HCV patients before and after antiviral treatment: preliminary results from the EMERALD study Sharon Levy Received Received
  SAT-200 Hepatocellular Carcinoma in Patients with Chronic Hepatitis C and Cirrhosis in Denmark Sofie Hallager Received Received
  FRI-200 Trends in hepatitis C-related mortality in Switzerland Francesco Negro Received Received
  THU-200 High prevalence of concomitant substance abuse and mental health disorders in an urban underserved FQHC-based hepatitis C virus treatment program Christian Boyd Ramers Received Received
  SAT-201 Gender differences on long-term outcomes in patients with dual chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection Pauline Nguyen Received Received
  THU-201 Diversity of the association of serumlevelsand genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C Chung-Feng Huang Received Received
  SAT-202 Impact of amino acid substitutions of HCV core region on hepatocarcinogenesis and hepatocellular oxidative stress in HCV infection Takeshi Chida Received Received
  FRI-202 Gender differences in liver disease progression by ethnicity in patients with chronic hepatitis C virus (HCV) mono-infection Pauline Nguyen Received Received
  THU-202 Characterisation of resistance associated substitutions in direct acting antivirals treatment naive patients with genotype 3 hepatitis C virus David Anthony Smith Received Received
  THU-203 Prevalence and genotype distribution of hepatitis C virus in Georgia: a 2015 nationwide population-based survey Davit Baliashvili Received Received
  FRI-203 Epidemiology and treatment of hepatitis C virus infection in China in 2013-2015: a hospital-based population study Peng Hu Received Received
  FRI-204 TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake Pietro Lampertico Received Received
  SAT-204 Resistance analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors Tami Pilot-Matias Received Received
  THU-204 Understanding factors associated with hepatitis c spontaneous viral clearance: a meta-analysis Dewi Nur Aisyah Received Received
  FRI-205 Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials Preethi Krishnan Received Received
  THU-205 Search for anti-hepatitis C virus positive patients lost in the health system: analysis of the absence of referring and the abandonment of the patient Elena Martinez Crespo Received Received
  THU-206 Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects Emanuela Messina Received Received
  SAT-206 Field evaluation of Xpert HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples Tanya Lynn Applegate Received Received
  FRI-206 A novel single daily fixed dose combination of sofosbuvir 400 mg + ribavirin1000 mg + egcg 400 mg is superior to the standard of care as an anti-viral and safer causing less hemolysis in patients with chronic hepatitis C Gamal Shiha Received Received
  SAT-207 Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools Tanya Lynn Applegate Received Received
  FRI-207 Active versus passive follow-up examination of patients with chronic hepatitis C during Sofosbuvir/Ledipasvir treatment Ganbolor Jargalsaikhan Received Received
  FRI-208 Rapid liver fibrosis regression after sustained virological response in HCV patients treated with direct acting antivirals Gema Maria Lledó Ibáñez Received Received
  SAT-208 Correlation between prevalence of hepatitis B and C virus infection and mortality of hepatocellular carcinoma in Uvs province, Mongolia Uurtsaikh Baatarsuren Received Received
  THU-208 Performance of the validated EGCRISC screening tool in chronic hepatitis C infection detection after application in the Egyptian setting Engy Mohamed El-Ghitany Received Received
  THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with daas is related to decline in liver inflammation Adam Winters Received Received
  SAT-209 Drop of FGF19 levels in patients with HCC development following DAA therapy for chronic hepatitis C Vanessa Stadlbauer Received Received
  FRI-209 Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study George Papatheodoridis Received Received
  THU-210 Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection Akira Kawano Received Received
  SAT-210 Regeneration linked miRNA in acute liver failure can predict clinical recompensation after DAA associated HCV cure: a novel biomarker to inform treatment ion in decompensated HCV cirrhosis? Siamak Salehi Received Received
  FRI-210 An outbreak of acute hepatitis C GT1b in onco-hematological patients. Treatment with Sofosbuvir+Ledipasvir and concomitant chemotherapy Giovanni Battista Gaeta Received Received
  FRI-211 Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: real life safety and efficacy Monica Schiavini Received Received
  SAT-211 Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression Wayel Zanjir Received Received
  SAT-212 Hepatitis C: Awareness Through to Treatment (HepCATT) study: Evaluation of an intervention designed to increase diagnosis and treatment of patients with hepatitis C virus infection in drug treatment settings Matthew Hickman Received Received
  FRI-212 DAA-based treatment in HCV and HIV/HCV co-infected patients in real world: data from a large single-centre experience Michele Milella Received Received
  THU-212 Markedly improvement of glycaemic control in diabetic patients with chronic hepatitis C achieving sustained virologic response after direct acting antiviral therapy: results of a prospective controlled study Alessia Ciancio Received Received
  SAT-213 Successful Hepatitis C treatment with direct acting antivirals leads to a rapid on-treatment decrease of liver stiffness with a slower gradual decrease of spleen stiffness Wim Verlinden Received Received
  THU-213 Impact of IL28B genotype on response rates in hepatitis C virus cirrhotic patients treated with new DAA regimens: experience of a single center Paola Ponzo Received Received
  THU-214 Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone Alison Boyle Received Received
  SAT-214 Epidemiology of hepatitis C infections in patient population in Northeastern China: a cross-sectional study Yue Hu Received Received
  FRI-214 Real world outcomes of DAA therapy for chronic hepatitis C virus infection in the HCV Research UK National cohort Michelle Cheung Received Received
  SAT-215 Elevated serum wisteria floribunda agglutinin-positive mac-2-binding protein levels associated with risks of diabetes and end-stage renal diseases among patients with hepatitis C virus infection Yu-Ju Lin Received Received
  THU-215 Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study Anand P. Chokkalingam Received Received
  THU-216 Persistence of hepatitis c virus core antigenemia after sustained virological response is associated with worsening of liver function and increased risk of hepatocellular carcinoma Amr Shaaban Hanafy Received Received
  SAT-216 The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States Yuri Sanchez Gonzalez Received Received
  FRI-216 Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life Guia Cerretelli Received Received
  FRI-217 Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago Harel Dahari Received Received
  SAT-217 Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy outcomes: A real-world observation Yuri Sanchez Gonzalez Received Received
  THU-217 SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C An K. Le Received Received
  THU-218 Risk of hepatitis B virus reactivation during exposure to hepatitis C virus treatment: an analysis of US ambulatory electronic medical record data Anand P. Chokkalingam Received Received
  SAT-218 Health-related quality of life in children with hepatitis C viral (HCV) infection treated with Sofosbuvir and Ribavirin Zobair M Younossi Received Received
  FRI-218 Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies – a prospective observational study of 136 patients Harrys Antonio Torres Received Received
  SAT-219 Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life Zoe Mariño Received Received
  THU-219 Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older Anca Trifan Received Received
  FRI-219 Full dose, daily sofosbuvir treatment in end-stage renal disease: tolerability & safety of largest ESRD patient cohort exposed to this drug Hector Enrique Nazario Received Received
  FRI-220 Excellent cure rates in largest ESRD patient cohort who completed treatment with full dose, daily sofosbuvir-based regimens Hector Enrique Nazario Received Received
  THU-220 Early regression of liver fibrosis evaluated by non-invasive methods after successful antiviral therapy in patients with HCV genotype 1b compensated cirrhosis Anca Trifan Received Received
  SAT-220 Pre-emptive post-liver transplant hepatitis C virus treatment with daas: proof of concept from a pilot study Luisa Pasulo Received Received
  SAT-221 High sustained viral response among hepatitis C virus genotype 3 patients with advanced liver fibrosis - real-world data of HCV elimination program in Georgia Maia Butsashvili Received Received
  FRI-221 The „HCV Advisor" App - A web-based mobile application to identify suitable treatments with direct antiviral agents for chronic hepatitis C infection Heiko Fruehauf Received Received
  FRI-222 Impact of directly acting antiviral drugs during treatment of decompensated cirrhosis with chronic hepatitis C Vivek Anand Saraswat Received Received
  THU-222 The effect of ribavirin dosage on the kinetics of viral load decline and drug exposures in plasma and liver with OBV/PTV/r + DSV treatment in patients with chronic hepatitis C virus genotype 1a infection Andrew H Talal Received Received
  FRI-223 New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society Hugo Cheinquer H Received Received
  SAT-223 Impact of sustained virological response with DAAs in patients with compensated HCV cirrhosis and endoscopic esophageal varices study Marc Puigvehí Received Received
  SAT-224 Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience Marco Sanduzzi Zamparelli Received Received
  THU-224 Liver stiffness evaluated by means of ARFI is related not only to fibrosis in patients with hepatitis C virus-related chronic hepatitis Annamaria Gesualdo Received Received
  FRI-224 Ribavirin free versus Ribavirin containing therapy with all second generation direct acting antivirals for the treatment of hepatitis C virus genotype 1 infection; a pooled analysis of 4501 patients Hussien Ahmed Received Received
  THU-225 Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study Anne Lindebo Holm Oevrehus Received Received
  FRI-225 Sustained Viral Response in patients who fail to complete hepatitis C treatment with Direct Acting Antivirals Iain Hay Received Received
  FRI-226 Response guided addition of Sofosbuvir to pegylated interferon and ribavirin cures greater than 90% of patients with Genotype 3 infection and F0-2 disease Iain Hay Received Received
  THU-226 Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy Francesca Ceccherini-Silberstein Received Received
  SAT-226 Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study Maria-Carlota Londoño Received Received
  THU-227 Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study Antonio Massimo Ippolito Received Received
  THU-228 High sustained virological response rates in hepatitis C genotypes 1a and 4 patients treated with elbasvir and grazoprevir and basal viremia >800.000 UI/mL Antonio Olveira Received Received
  FRI-228 Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry Irene Cacciola Received Received
  SAT-228 Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: The CHAMPS Study Mark Sulkowski Received Received
  FRI-229 No adverse renal side effects in patients with mild to moderate renal dysfunction treated with Sofosbuvir Iris Kuo Received Received
  FRI-230 The presence of two or more baseline NS5A resistance associated substitutions jeopardizes DAA treatment success in HCV patients Itziar Carrasco Garcia Received Received
  SAT-230 Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection Mark Sulkowski Received Received
  THU-230 The effect of directly acting antivirals treatment on inflammatory status in HCV-infected patients, including those with recurrence of HCV-infection after liver transplantation: preliminary results of a prospective monocentric pilot study Barbara Lattanzi Received Received
  SAT-231 Treatment of patients with hepatitis C virus genotype 5 and 6: descriptive analysis of the Hepa-C registry Marta Hernández Conde Received Received
  SAT-232 Hepatitis C treatment with direct antiviral agents induce mild renal impairment Marta Tejedor Bravo Received Received
  THU-232 The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments Behzad Hajarizadeh Received Received
  FRI-232 Hepatitis C therapy delivered within and by a community addiction service: real life data shows SVR rates 90 Jacquelyn McGinley Received Received
  THU-233 Reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection in a community based setting Beshoy Yanny Received Received
  SAT-233 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: Integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis Ed Gane Received Received
  SAT-234 Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR =30ml/min): a case series Joseph Llewellyn Received Received
  THU-234 Grazoprevir-elbasvir based therapy is safe and effective in patients with chronic kidney disease GFR <30 and patients with end stage renal disease who are on renal replacement therapy in a community based setting Beshoy Yanny Received Received
  FRI-234 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study Jason Grebely Received Received
  FRI-235 SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy Jason Grebely Received Received
  THU-235 Direct acting antivirals improve neutrophil phagocytic capacity in chronic hepatitis C Bettina Leber Received Received
  SAT-235 Plasma miR-122 levels in chronic hepatitis C patients achieving sustained virological response following DAA treatment with and without previous anti-miR-122 (RG-101) dosing Meike H. van der Ree Received Received
  SAT-236 The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis Michael Manns Received Received
  THU-236 Using all-oral hepatitis C virus therapy to reduce recurrent viremia and increase SVR Arshia Alimohammadi Received Received
  FRI-237 HepCom: Impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C Javier Ampuero Received Received
  SAT-238 Drug-drug interactions of high prevalence in a real world hepatitis C treatment setting: the impact on treatment and the implications for patient management Miriam Coghlan Received Received
  THU-238 Feasibility and acceptability of a group medical visit intervention to improve hepatitis C virus treatment uptake among persons who inject drugs (PWID) in a primary care setting Brianna Norton Received Received
  FRI-238 Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis Jean-Francois Dufour Received Received
  THU-239 Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: Retrospective data analyses from the TRIO Network Bruce Bacon Received Received
  FRI-239 Analysis of the real-world treatment effectiveness of elbasvir/grazoprevir Jeffrey Scott Mc Combs Received Received
  FRI-240 Obesity and high body weights predict ledipasvir/sofosbuvir treatment failure David J. Witt Received Received
  THU-240 Outcome of patients with compensated liver cirrhosis with hepatitis B virus+hepatitis C virus coinfection treated with paritaprevir/ ombitasvir /ritonavir, dasabuvir with ribavirin: a national cohort study Carmen Preda Received Received
  THU-241 Second generation direct acting antiviral agents improve clinical resource utilization required for hepatitis C eradication Charles Mahoney Received Received
  FRI-241 Hepatitis C Care Continuum: Experience of an Emergency department screening programme Jennifer Lee Received Received
  SAT-241 Outcomes of daclatasvir + sofosbuvir + riba in HEP C G3 patients who relapsed with SOF + RIBA combination therapy Muzaffar Lateef Gill Received Received
  SAT-242 Comparison of vibration-controlled transient elastography (VCTE) with aspartate aminotransferase-to-platelet ratio Index (APRI) and platelet count for Identification of esophageal varices in patients with cirrhosis Muzaffar Lateef Gill Received Received
  FRI-242 Changes in markers of liver function in hepatitis C virus genotype 1b Asian patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin in the ONYX-II study Jeong Heo Received Received
  THU-242 Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis Cheng Wang Received Received
  THU-243 Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus -infected patients treated with recommended regimens Chiara Masetti Received Received
  FRI-243 Cure of chronic hepatitis C patients receiving direct-acting antivirals correlated with partial restoration of HCV-specific T cell responses Jijing Shi Received Received
  SAT-243 Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C Naoki Kawagishi Received Received
  FRI-244 Fibrosis regression in chronic hepatitis C patients after treatment with direct-acting antiviral agents is more effective than before – comparison of different noninvasive methods Joana Rita Oliveira Alves Rita Carvalho Received Received
  THU-244 Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease Chiara Masetti Received Received
  SAT-244 Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network Naoky Tsai Received Received
  SAT-245 Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data Nathalie Scherz Received Received
  FRI-245 Total cholesterol and low-density lipoprotein increases after treatment with direct-acting antiviral agents – Implications in the future? Joana Rita Oliveira Alves Santos Carvalho Received Received
  FRI-246 Successful implementation of HCV treatment in two large HIV clinics in Amsterdam: HCV treatment cascade of care Job Saris Received Received
  SAT-246 Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study Naveed Janjua Received Received
  FRI-247 Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) Johannes Vermehren Received Received
  SAT-247 Assessment of glomerular filtration rate in hepatitis C virus patients after reaching sustained virologic response Nelson Roberto Reyes Campos Received Received
  SAT-248 DAA-based regimens in HBsAg/anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation Nicola Coppola Received Received
  FRI-248 Clinical and virological characteristics of patients with chronic hepatitis C virus (HVC) infection and failure to multiple direct acting antiviral (DAA) therapies Johannes Vermehren Received Received
  THU-249 Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection Christophe Hezode Received Received
  SAT-249 Real world experience of direct acting antiviral agents in hepatitis C virus genotype 4: encouraging outcomes from a UK-based cohort Nina Stafford Received Received
  FRI-249 Efficacy and safety of Simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy John Dillon Received Received
  FRI-250 Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis – final results of the REV1TAL study John Samuel Lubel Received Received
  THU-250 Treatment of "acute" hepatitis C virus in human immunodeficiency virus-infected men with short-course sofosbuvir/ledipasvir Daniel Seth Fierer Received Received
  FRI-252 Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany Jörg Petersen Received Received
  SAT-252 Changes in the lipid profile in hepatitis C virus infected patients treated with direct-acting antivirals Pedro Linares Received Received
  THU-253 Effects of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection on serotonin metabolism, depression scores and fatigue Daphne Hahn Received Received
  FRI-253 Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals José Luis Calleja Panero Received Received
  FRI-254 Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice José Luis Calleja Panero Received Received
  THU-254 Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin Darshan Mehta Received Received
  THU-255 Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia David Metreveli Received Received
  FRI-255 INTER-COLLaborative HEPatitis C: real-world treatment of hepatitis C patients by non-expert specialist providers in small and medium size Portuguese hospitals Jose Ramos Received Received
  SAT-255 Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world Philippe Halfon Received Received
  SAT-256 Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing Qian Chen Received Received
  FRI-256 Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection Joseph S Doyle Received Received
  THU-256 Hepatitis C: year 1 real life results from the All Wales hepatitis C roll out programme David Samuel Received Received
  FRI-257 Short-term effect of DAA IFN-free regimens on liver stiffness Juan A. Pineda Received Received
  SAT-257 Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study Raffaella Lionetti Received Received
  SAT-258 Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1- infected patients with compensated cirrhosis and multiple comorbidities Raluca Cezara Popa Received Received
  THU-258 12 weeks of sofosbuvir, daclatasvir and ribavirin for GT3 patients with cirrhosis Debbie Troland Received Received
  FRI-258 Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome Julia Dietz Received Received
  SAT-259 An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks Jacinta A. Holmes Received Received
  FRI-259 High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis Julia Schwarz Received Received
  THU-259 Retreatment of hepatitis C virus daa failures in real life: Easy and difficult to cure patients Denis Ouzan Received Received
  FRI-260 Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: Real life data from the HEPAVIR-DAA Cohort Juan A Pineda Received Received
  SAT-260 Lipid modification in hepatitis C virus-monoinfected patients treated with direct acting antivirals Regina Juanbeltz Received Received
  THU-260 Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients Diletta Barbanotti Received Received
  THU-261 Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in hepatitis C virus child-A cirrhosis Donatella Palazzo Received Received
  SAT-261 Real world experience: Treating Hepatitis C in Alice Springs, Australia 2007-16 Robert Gordon Batey Received Received
  THU-262 Prospective study of autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct acting antivirals Doroteo Acero Fernández Received Received
  FRI-262 CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis Fumitaka Suzuk Received Received
  SAT-262 Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN Roberta D´ambrosio Received Received
  SAT-263 Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting Filomena Morisco Received Received
  FRI-263 Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis Tsunamasa Watanabe Received Received
  THU-263 Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis Edward Gane Received Received
  SAT-264 Sustained virological response in HCV patients treated with daclatasvirsofosbuvir, with or without ribavirin: a multicenter, field-practice experience Rodolfo Sacco Received Received
  SAT-265 DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment Rosanna Villani Received Received
  FRI-265 Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia Kerstin Hartig-Lavie Received Received
  SAT-266 Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy Sabela Lens Received Received
  THU-267 Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort Eiichi Ogawa Received Received
  THU-268 High efficacy of 8 weeks of ledipasvir/sofosbuvir in real-world treatment Eleanor Wilson Received Received
  SAT-268 Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir+dasabuvir regimen on patient`s health related quality of life: Analysis of Phase 3a and phase 3b clinical trials Darshan Mehta Received Received
  THU-269 Changes in renal function in patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents Eleni Theocharidou Received Received
  SAT-269 Drop-out rate due to HCC progression is not affected by HCV eradication with DAAs in patients awaiting liver transplantation Sarah Shalaby Received Received
  FRI-270 Antiviral therapy in patients with chronic hepatitis C related hepatocellular carcinoma responding to palliative treatment Kwan Sik Lee Received Received
  THU-270 Management of drug-interactions with DAAs in Dutch human immunodeficiency virus/hepatitis C virus co-infected patients: adequate but not perfect Elise Joëlle Smolders Received Received
  SAT-270 Results of hepatitis C treatment program among people who inject drugs Sergii Filippovych Received Received
  FRI-271 Comparison of efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients Lai Wei Received Received
  THU-271 Improvement of glycemic state among responders to sofosbuvir – based DAAs Shereen Abdel Alem Received Received
  SAT-271 On-treatment HCV RNA monitoring is not a cost-effective means of identifying non-adherence and has no predictive value Shirin Demma Received Received
  FRI-272 Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results Lai Wei Received Received
  SAT-272 Characterization of novel GT-1b resistant-associated substitutions (RASs) selected by NS5A inhibitor-based regimens Slim Fourati Received Received
  THU-272 Prevalence of serum non organ specific antibodies in patients with chronic hepatitis c and their influence in direct-acting antivirals therapy Endrit Shahini Received Received
  SAT-273 Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1 6 and chronic kidney disease: an integrated analysis Stan Pol Received Received
  FRI-273 Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results Wan-Long Chuang Received Received
  FRI-274 Efficacy and safety of Direct-Acting Antiviral Drugs in patients with thalassemia major and crhonic hepatitis C: a preliminary report of a single italian center Laura Ponti Received Received
  THU-274 Lack of clinical benefit of direct acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis Estefania Berge Received Received
  THU-275 High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry Ester Badia Aranda Received Received
  FRI-275 No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data Anand P. Chokkalingam Received Received
  FRI-276 In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir Leen Vijgen Received Received
  THU-276 Evolution of platelets in chronic hepatitis C infected patients and advanced liver fibrosis after direct-acting antiviral treatment Ester Badia Aranda Received Received
  SAT-276 Effect of eradicating hepatitis c on alanine aminotransferase levels Stefan Mauss Received Received
  SAT-277 Worsening of serum lipid profile after direct acting antiviral treatment Stefano Gitto Received Received
  FRI-277 Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis Letizia Marinaro Received Received
  FRI-278 Decrease of Interleukin-6 and Interleukin-8 blood levels after successful interferon-free anti-HCV treatment Lorenzo Badia Received Received
  SAT-278 Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy Stephan Moser Received Received
  THU-278 The eradicate-C study-curing people who are actively injecting drugs of hepatitis C: the first step to elimination Farsana Ahmad Received Received
  SAT-279 Real-world treatment utilization and results in the renaissance of HCV Care: Analyses of treatment for 7,550 Patients from the TRIO Network Steven Flamm Received Received
  FRI-279 Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort Loreta A Kondili Received Received
  THU-279 Comorbidities and metabolic disorders associated to hepatitis C virus infection: their implications in the severity of the disease and overall mortality risk Fátima Serejo Received Received
  FRI-280 Clinical characterization and economic impact evaluation of anti- HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Loreta A. Kondili Received Received
  THU-280 Real life retreatment of patients failing DAAs in Spain: data from the HCVREsp cohort Federico García Received Received
  FRI-281 Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer Luisa Cavalletto Received Received
  THU-281 Low rate of drug-drug interaction management during interferon-free simeprevir therapy - An integrated analysis of interventional and observational clinical studies Fiona Marra Received Received
  FRI-282 Genotype 3 infection in DAA era: reports of a real life NORTHERN ITALY NETWORK FOR VIRAL HEPATITIS after 2 years by the start Luisa Pasulo Received Received
  SAT-282 The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy Tea Lund Laursen Received Received
  THU-282 Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice Fiona Marra Received Received
  THU-283 Changes in liver stiffness assessment in chronic hepatitis c patients treated with direct-acting antivirals: monocentric experience between 2015 and 2016 Elke Maria Erne Received Received
  SAT-283 Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia Tengiz Tsertsvadze Received Received
  FRI-283 The old patient in DAA era: real life reports on 5925 patients from the Lombardy HCV Network Luisa Pasulo Received Received
  FRI-284 Virus-specific coexpression of T-bet and Eomes defines highly functional CD8 and CD4 T cells in hepatitis B virus infection Hadi Karimzadeh Received Received
  SAT-284 Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia Tengiz Tsertsvadze Received Received
  THU-284 Cost-effectiveness of elbasvir-grazoprevir association for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France Franck Maunoury Received Received
  FRI-285 Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E Jana Al-Ayoubi Received Received
  THU-285 Efficacy and safety of the fixed-dose combination regimen of MK3 MK-3682/grazoprevir/ruzasvir with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2) Frank Dutko Received Received
  THU-286 Chronic hepatitis C in children in the Russian Federation: a multicenter study Tamara Skvortsova Received Received
  SAT-286 Outcome of liver transplantation in HCV infected patients – implications for antiviral treatment decisions Thomas Kuntzen Received Received
  FRI-286 The impact of ERAP1 polymorphisms on virus-specific CD8+ T cell responses in an HLA*B27+ patient with acute hepatitis C virus infection Janine Kemming* Received Received
  SAT-287 Virological and clinical significance of detectable HCV-RNA below limit of quantification at End-of-Treatment in patients treated with direct antiviral agents Ubaldo Visco Comandini Received Received
  SAT-288 The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution Valeria Cento Received Received
  THU-288 Neutralizing activity of non-polyreactive monoclonal antibodies directed against the hepatitis C virus E2 glycoprotein isolated from patients with spontaneous resolution Anne Olbrich Received Received
  THU-289 Infectious hepatitis C virus particle assembly is inhibited by paritaprevir and ombitasvir David R Mcgivern Received Received
  SAT-289 Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis Victor Virlogeux Received Received
  FRI-290 Pegylated interferon alpha treatment rapidly clears hepatitis E virus infections in humanized mice Thomas Vanwolleghem Received Received
  THU-290 Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals Elena Perpiñán Mas Received Received
  SAT-290 Liver decompensation predicts ribavirin overexposure in HCV cirrhotic patients treated with direct-acting antiviral agents Viola Guardigni Received Received
  FRI-291 KLRG1 impairs antiviral immunity of NK-cell in Individuals with Chronic Hepatitis B Virus Infection via the Akt pathway Ming-Hong Li Received Received
  SAT-291 Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies Wan-Long Chuang Received Received
  SAT-292 Liver function as measured by albumin-bilirubin score within decompensated patients receiving direct acting antiviral therapy within the Expanded Access Programme Philip Johnson Received Received
  FRI-292 B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function Poonam Mathur Received Received
  THU-292 Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C Georg Dultz Received Received
  FRI-293 Mucosal-associated invariant T lymphocytes are declined, activated, and exhausted in peripheral in chronic HBV-infected patients Qian Liu Received Received
  SAT-293 Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C after living donor liver transplantation: a Japanese multicenter experience Yoshihide Ueda Received Received
  FRI-294 Metabolic properties of epigenetically regulated adaptive versus conventional NK cells are conserved in chronic viral hepatitis Anita Schuch Received Received
  SAT-294 Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients Yuri Sanchez Gonzalez Received Received
  THU-294 Allelic variantes of Aurora B kinase gene can be related with fibrosis progression in chronic hepatitis C Irene Francisco-Recuero Received Received
  SAT-295 A budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States Yuri Sanchez Gonzalez Received Received
  FRI-295 CCR5 T cells are primary responders to HCV subject to exhaustion and contribute to ongoing hepatic inflammation Shikha Shrivastava Received Received
  SAT-296 Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment Yutaka Yasui Received Received
  FRI-296 Myeloid-derived suppressor cells: key players mediating immunosuppression via induction of regulatory T-cell by TGF-ß and IL-10 driven pathways in chronic HBV infection Sourina Pal Received Received
  THU-296 Hepatocyte single cell sequencing to identify transcript modulation by hepatitis C virus Jose Daniel Debes Received Received
  THU-297 Multiple ascending dose study of seraprevir potassium, a nonstructural protein 3/4A replication complex inhibitor, in patients infected with hepatitis C virus junqi niu Received Received
  SAT-297 Elbasvir/Grazoprevir effectiveness in patients with chronic hepatitis C and chronic kidney disease: real-world experience from the TRIO Network Zobair Younossi Received Received
  FRI-297 Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy Upkar S. Gill Received Received
  FRI-298 Human leukocyte antigen and IL28B polymorphisms independently associated with hepatitis C virus RNA spontaneous clearance: a study from REVEAL-HCV cohort Yu-Han Huang Received Received
  THU-298 Inosine triphosphate pyrophosphatase enhances the effect of ribavirin on hepatitis C virus cell culture infection Kristina Nyström Received Received
  SAT-298 HEV as a cause of acute hepatitis acquired in Switzerland Montserrat Fraga Christinet Received Received
  THU-299 Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication Maged Saleh Received Received
  SAT-299 Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study Pierre Gholam Received Received
  SAT-300 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease Roberta Forlano Received Received
  THU-300 Viral load at 15 days after liver transplantation as a good predictor of fast liver fibrosis progression Meritxell Llorens Received Received
  FRI-300 Disease spectrum of alcoholic liver disease in beijing 302 hospital from 2002-2013: a large tertiary referral hospital experience from 7422 patients Ang Huang Received Received
  SAT-301 Prevalence of combined PNPLA3 and GCKR variant genotype is increased in patients with risk factors for alcoholic or non-alcoholic liver disease who have clinically significant serum pro-collagen III levels Prarthana Thiagarajan Received Received
  THU-301 In vitro inhibition of hepatitis C virus with ribavirin is strain dependent and leads to RNA mutagenesis Niels Mejer Received Received
  FRI-301 MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients Antonio Riva Received Received
  FRI-302 Variation in the use of corticosteroids for the treatment of acute severe alcoholic hepatitis in the post-STOPAH era: results of a UK national survey Ashwin Dhanda Received Received
  SAT-302 Prevalence of nonalcoholic fatty liver disease in lean adolescents in the United States: an analysis of national health and nutrition examination survey data Naim Alkhouri Received Received
  THU-302 MIV-802, a uridine nucleotide prodrug, is a more potent inhibitor of hepatitis C virus genotype 3 replication than sofosbuvir Richard Bethell Received Received
  THU-303 Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance Sofia R Bartlett Received Received
  SAT-303 Prevalence and risk factors of nonalcoholic fatty liver disease in metabolically healthy obese adolescents in the United States: an analysis of national health and nutrition examination survey data Naim Alkhouri Received Received
  FRI-303 Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16-) monocytes Ashwin Dhanda Received Received
  FRI-304 No consensus among nutritional assessment tools for identification of malnutrition in patients with alcoholic liver disease Chetan Ramesh Kalal Received Received
  SAT-304 Can modest alcohol intake be dismissed as a co-factor in diabetic patients with non-alcoholic fatty liver disease? Preya Janubhai Patel Received Received
  FRI-305 Ethanol-induced depletion of Akkermansia muciniphila drives alcoholic liver disease Christoph Grander Received Received
  THU-305 Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes Teresa Ng Received Received
  SAT-305 Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score Raluca Pais Received Received
  THU-306 Transcriptional response to hepatitis C virus infection in the human liver Tuyana Boldanova Received Received
  SAT-306 Ethnicity and outcomes in non alcoholic fatty liver disease: prospective evaluation of 1500 cases Richard Parker Received Received
  SAT-307 Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine histological images in patients with non-alcoholic fatty liver disease Roberta Forlano Received Received
  FRI-307 Effect of alcohol on the IL-6 mediated inflammatory response in a new mouse model of acute-on-chronic liver injury Ersin Karatayli Received Received
  THU-307 Exosomal miRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection Zhongtian Qi Received Received
  THU-308 Direct antiviral agents therapy can induce a partial restoration of the antiviral immune functions in patients with chronic hepatitis C virus infection Amalia Penna Received Received
  FRI-308 A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption Flaminia Ferri Received Received
  FRI-309 Differential gender-related impact of PNPLA3 and CD14 polymorphism on the risk of developing alcoholic cirrhosis Flaminia Ferri Received Received
  THU-309 Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in hepatitis C virus infected patients Andrea Martini Received Received
  SAT-309 Obesity and steatosis severity affect diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease Yong Jin Jung Received Received
  THU-310 Preferential recognition of hepatitis B virus-DNA integrated target by hepatitis B virus-specific CD8 T cells Atefeh Khakpoor Received Received
  FRI-310 Hair ethyl glucuronide is a highly accurate and objective biomarker of continued alcohol use in patients with alcoholic cirrhosis Frederik Nevens Received Received
  SAT-310 Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease Salvatore Petta Received Received
  SAT-311 Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population Salvatore Petta Received Received
  THU-311 Impaired T follicular helper cell-B cell axis in chronic HBV infection despite long-term antiviral treatment Bhawna Poonia Received Received
  FRI-311 The effect of nurse performed telemedical video consultations for patients suffering from alcohol-related liver cirrhosis Ghita Bellis Thygesen Received Received
  THU-312 MAIT cell frequency and function in blood and liver of hepatitis C virus mono- and hepatitis C virus/human immunodeficiency virus co-infected patients with mild versus advanced fibrosis Boris Beudeker Received Received
  SAT-312 A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease Sang Bong Ahn Received Received
  FRI-312 Carcinogenic Etheno DNA-adducts in alcohol liver disease: correlation with cytochrome P-4502E1 and fibrosis Helmut Karl Seitz Received Received
  SAT-313 Dynamic FDG-PET study of liver inflammation in non-alcoholic fatty liver disease Souvik Sarkar Received Received
  THU-313 Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope Chai Fen Soon Received Received
  FRI-313 Iron promotes ADAM-17 mediated sCD163: TNF-a liberation and modulates inflammation in severe alcoholic hepatitis Jaswinder Singh Maras Received Received
  THU-314 Macrophage-derived extracellular vesicles mediate a long-lasting innate immune response against hepatitis C virus Chengcong Cai Received Received
  FRI-314 Physiologic Staging in alcoholic Liver Disease Predicts Death and Monitors Recovery John Carl Hoefs Received Received
  SAT-315 Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies Stuart Mcpherson Received Received
  THU-315 Hepatitis B virus affects dendritic cell activation and their crosstalk with natural killer cells Claudia De Pasquale Received Received
  FRI-315 Effects of probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) in the treatment of mild alcoholic hepatitis: randomized controlled multicenter study Ki Tae Suk Received Received
  SAT-316 Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis Sven Marcel Francque Received Received
  THU-317 N22 region based dot blot assay: an alternative to PCR for detection of Torque teno virus infection Dhananjay Singh Mankotia Received Received
  FRI-317 Autologous hematopoietic stem cell transplantation into the liver: impact on hepatic macrophagic expansion and gene expression Nicolas Lanthier Received Received
  SAT-317 Association of A313G polymorphism of GSTP1 gene with certain biochemical markers of liver injury, pro- and anti-inflammatory cytokines in patients with nonalcoholic fatty liver disease Vasyl Prysyazhnyuk Received Received
  THU-318 NS3 inhibition coupled with potent direct acting antiviral combinations leads to enhanced hepatitis C virus specific immunity in hepatitis C virus-human immunodeficiency virus co-infected patients Eleanor McKenna Pitt Wilson Received Received
  THU-319 Toll-like receptor 5 polymorphism at position c.1846T>C is associated with the development of hepatocellular carcinoma in caucasians with chronic hepatitis B infection Janett Fischer Received Received
  FRI-319 Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease Jian Gao Fan Received Received
  SAT-319 Non-alcoholic fatty liver disease – demographic features, risk factors and treatment practices across the Asia Pacific region – the GO ASIA initiative Wah Kheong Chan Received Received
  FRI-320 Taste and appetite disorders in patients with non-alcoholic fatty liver disease Joanna Musialik Received Received
  SAT-320 Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity William Alazawi Received Received
  SAT-321 Periodontitis is strongly associated with NAFLD in the NHANES III cohort and in an independent prospective study, is more common in those with biopsy-proven advanced compared to mild liver disease William Alazawi Received Received
  FRI-321 Steatohepatitis: differential features on quantitative liver-spleen scan John Carl Hoefs Received Received
  THU-321 TRAF1 as a marker of exhaustion during chronic hepatitis C Elia Moreno Received Received
  FRI-322 Vitamin D serum levels are only marginally lower in hepatic steatosis and do not correlate with Vitamin D dietary ingestion Jorge Leitão Received Received
  SAT-322 Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis– a phase 1b study William Kemp Received Received
  SAT-323 Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment William Malcolm Rosenberg Received Received
  FRI-323 Hepatic steatosis in an adult population: stronger correlation with the presence of obesity and insulin resistance than with the dietary pattern. Results from a cross-sectional study Jorge Leitão Received Received
  FRI-324 Evaluation of a novel nurse-led one-stop clinic for patients referred for investigation of suspected non-alcoholic fatty liver disease Kirsty Fancey Received Received
  SAT-324 Comparison of risk factors for nonalcoholic steatohepatitis and advanced fibrosis between patients with obese and non-obese nonalcoholic fatty liver disease Won Kim Received Received
  THU-324 No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients Femke Stelma Received Received
  THU-325 Ki67, cyclin D and caspase 3 allow distinction of two sub-groups of alcoholic patients at early stages of alcoholic liver disease Peter Stärkel Received Received
  SAT-325 Assessment of the hepatic steatosis using controlled attenuation parameter (CAP) measured with transient elastography in healthy population Young Mi Hong Received Received
  FRI-325 High liver iron in biopsy of NAFLD patients is a predictor for cardiovascular and liver-related mortality Elmar Aigner Received Received
  FRI-326 The COMMANDS study: improving community-based diagnosis and management of non-alcoholic fatty liver disease Laura Burke Received Received
  SAT-326 Health-related quality of life in patients with non-alcoholic fatty liver disease Yvonne Huber Received Received
  SAT-327 Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) Zobair M Younossi Received Received
  FRI-327 Effective dietary interventions for non-alcoholic fatty liver disease: barriers and facilitators to adoption of a Mediterranean diet in a northern European patient population Laura Haigh Received Received
  THU-327 Development of a novel murine model of acute alcoholic hepatitis Richard Wilkin Received Received
  FRI-328 Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: The Rotterdam Study Louise Johanna Maria Alferink Received Received
  SAT-328 Can atherosclerotic cardiovascular risk score (ASCVD) predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)? Zobair M Younossi Received Received
  THU-328 Evaluation of potential futility in alcoholic hepatitis – multicentre study Rita Barosa Received Received
  SAT-329 Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development Marica Meroni Received Received
  FRI-329 Severe histological liver phenotype of lean subjects with non-alcoholic fatty liver disease Lukas Denkmayr Received Received
  THU-329 Clinical criteria are of limited value for diagnosis of alcoholic steatohepatitis Rudolf E. Stauber Received Received
  THU-330 Drinking behaviour and rs738409:G in PNPLA3 are associated with slower recovery of liver function following severe alcoholic hepatitis Stephen R Atkinson Received Received
  FRI-330 NAFLD as an indication for liver transplantation in the Nordic countries – a cohort study during 1982-2015 Magnus Holmer Received Received
  SAT-331 Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASH Michael Feigh Received Received
  THU-331 Low serum transferrin indicates short-term mortality in severe alcoholic hepatitis Stephen Atkinson Received Received
  FRI-331 Effects of gene variants controlling vitamin D metabolism and serum levels on hepatic steatosis Malgorzata Jamka Received Received
  THU-332 Serum procalcitonin correlates with baseline renal function and predicts mortality in severe alcoholic hepatitis Stephen R Atkinson Received Received
  SAT-332 Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice Mitchell Bijnen Received Received
  FRI-333 Exploring the patient perceived impact of non-alcoholic steatohepatitis Maria-Magdalena Balp Received Received
  FRI-334 How often do we misclassify alcoholic as nonalcoholic fatty liver disease due the subjectivity in assessing alcohol consumption? Mariana Verdelho Machado Received Received
  SAT-334 Ingestion of wheat amylase trypsin inhibitors promotes a proinflammatory liver and adipose tissue phenotype in diet induced non-alcoholic fatty liver disease in mice Muhammad Ashfaq-Khan Received Received
  THU-334 Alcoholic hepatitis histological scores predict short-term survival in Asian patients with biopsy-proven alcoholic hepatitis Won Kim Received Received
  FRI-335 Nonalcoholic fatty liver with hepatic arterial buffer response strongly caused metabolic diseases, while bright pancreas was not associated with metabolic diseases - 5 years´ cohort Masashi Hirooka Received Received
  THU-335 Investigating immunomodulatory roles of CX3CR1 related with differentiation and functional polarization of kupffer cells Young-Sun Lee Received Received
  SAT-336 Clinical course and outcome of pregnancy in women with non alcoholic fatty liver disease Nasser Mousa Received Received
  THU-336 The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study Ahmet Uygun Received Received
  FRI-336 Liver steatosis and fibrosis in at-risk European HIV-monoinfected patients Maud Lemoine Received Received
  FRI-337 Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients Maud Lemoine Received Received
  SAT-337 Neurobehavioral disturbances and hyperammonemia are evident in rodent model of NAFLD prior to cirrhosis stages Natalia Arias Received Received
  FRI-338 Serologically assessed extracellular matrix remodeling is affected by bariatric surgery in morbidly obese NAFLD patients with 12 months follow-up Mette Juul Nielsen Received Received
  THU-338 Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States between 2005 and 2013 Alexander Le Nguyen Received Received
  SAT-339 The effect of elafibranor and obeticholic acid on NAFLD Activity score and fibrosis stage in a novel metabolic rat model of diet-induced and biopsy-confirmed NASH Niels Vrang Received Received
  FRI-339 First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects Bryan Laffitte Received Received
  THU-339 Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients Alexandra Feldman Received Received
  SAT-340 Precision-cut liver slices as an ex-vivo model for human NAFLD show hepatic progenitor cell activation and fibrogenesis Olivier Govaere Received Received
  FRI-340 SAF score effectively identifies NAFLD subjects at high risk of subsequent liverrelated but not cardiovascular or malignancy-associated mortality and morbidity Michael Strasser Received Received
  THU-340 Use of non-invasive methods to assess hepatic steatosis and advanced fibrosis in type-1 diabetic patients Amandeep Singh Received Received
  THU-341 Prevalence of non–alcoholic fatty liver disease and advanced fibrosis in type - 2 diabetic patients via non-invasive methods Naim Alkhouri Received Received
  FRI-341 An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis patients Mohammad Shahed Ashraf Received Received
  SAT-341 miR-21 ablation and obeticholic acid ameliorate NASH in mice Marta Bento Afonso Received Received
  SAT-342 Hepatic overexpression of chemerin attenuates expression of inflammatory and profibrotic genes in murine non-alcoholic steatohepatitis Rebekka Pohl Received Received
  THU-342 Validation of non-invasive fibrosis assessments in biopsy-proven non-alcoholic fatty liver disease Andreas Drolz Received Received
  FRI-342 The diagnostic accuracy of vibration controlled transient elastography for cirrhosis in subjects with nonalcoholic fatty liver disease Mohammad Shadab Siddiqui Received Received
  FRI-343 Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial Natalia Bosak Received Received
  FRI-344 Changing eating behavior by motivational and controlled program during 12 weeks reduce weight, cytokeratin 18 levels and steatosis in patient with NAFLD Nataliia Dynnyk Received Received
  THU-345 Individuation of presence and combination of genetic risk factors may help to refine the risk for most severe forms of NAFLD Chiara Dell´Unto Received Received
  FRI-345 Influence of non-alcoholic fatty liver diease on the course of stable coronary heart disease Iryna Igorivna Vakalyuk Received Received
  FRI-346 Role of a-ketoglutarate and ß-hydroxybutyrate in morbid obesity-associated non-alcoholic fatty liver disease: metabolomic approach Noemí Cabré Received Received
  SAT-346 Prolonged-release pirfenidone is a dual activator for PPARalpha and PPARgamma and improves NASH features induced by high fat/carbohydrate diet Roberto Rodriguez-Echevarria Received Received
  SAT-347 Steatogenic compounds induce triglyceride accumulation by multiple mechanisms in hepatocyte-like cells generated from human skin-derived precursors Robim M Rodrigues Received Received
  FRI-347 PNPLA3, TM6SF2 and MBOAT7 genotypes and coronary artery disease Nynke Simons Received Received
  THU-347 A new French paradox: morbidly obese patients with NASH have less bulimia than those without NASH Clemence M Canivet Received Received
  SAT-348 The severity of portal inflammation is associated with hepatic fibrosis stage and components of metabolic syndrome in NAFLD Sae Kyung Joo Received Received
  THU-348 Simple sugar consumption associated abnormal aminotransferase activity without intrahepatic fat: A cross sectional observational study Dae Won Jun Received Received
  THU-349 Autonomic function is impaired across the spectrum of NAFLD David Houghton Received Received
  THU-350 Cardiovascular risk factors are independent of fibrosis severity in NAFLD Davide Roccarina Received Received
  FRI-350 Sprint interval exercise training reduces intrahepatic, visceral and subcutaneous abdominal fat despite no change in body weight, but has variable effects on whole-body insulin sensitivity Jack Alistair Sargeant Received Received
  FRI-351 Hepatocyte nuclear factor 4a played a different role in lipotoxicity and bile acid toxicity in non-alcoholic fatty liver disease model Jai Sun Lee Received Received
  SAT-351 Hepatotropic effects of granulocyte colony stimulating factor in non-alcoholic fatty liver disease: beyond marrow cell mobilization Sang Bong Ahn Received Received
  THU-351 Estimation of serum "true collagen type III formation" (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort Diana Julie Leeming Received Received
  THU-352 Nonalcoholic fatty liver disease and development of chronic kidney disease: a retrospective cohort study Dong Hyun Sinn Received Received
  SAT-352 Role of group 2 innate lymphoid cells in the prevention of high-fat diet-induced nonalcoholic steatohepatitis by caffeine Shuhei Hayashi Received Received
  THU-353 Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD Eduardo Vilar Gómez Received Received
  FRI-353 Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor Jian Luo Received Received
  SAT-353 Genetic polymorphism of PTPRD (rs35929428) and risk of non-alcoholic fatty liver disease in Japanese Shunsuke Nakajima Received Received
  THU-354 Performance of the fibroscan and other noninvasive scales for detecting hepatic fibrosis in patients with nonalcoholic fatty liver disease Esteban Saez Received Received
  SAT-354 Therapeutic effect of cerium oxide nanoparticles (CeO2NPs) in rats with diet-induced non-alcoholic steatohepatitis Silvia Carvajal Received Received
  FRI-354 Elevated hepatic and adipose hepcidin expression in patients with advanced NAFLD fibrosis John Denis Ryan Received Received
  SAT-355 Annexin A1 supplementation prevents the progression to fibrosis of nonalcoholic steatoepatitis (NASH) Stefania Bruzzì Received Received
  THU-355 The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients Esther Nistal Received Received
  THU-357 Low vitamin D level is not associated with severity of non-alcoholic fatty liver disease in morbidly obese patients Ana de Lourdes Candolo Martinelli Received Received
  FRI-357 Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mouse Joost Willebrords Received Received
  SAT-357 Inhibition of IL6 trans-signaling leads to gut microbiota-dependant mature-onset obesity and metabolic syndrome Eithan Galun Received Received
  FRI-358 Aramchol reduces established fibrosis in MCD diet animal model José M Mato Received Received
  SAT-358 Adipose type I interferon signalling protects against metabolic dysfunction Timon Adolph Received Received
  THU-358 Fasting serum bile acids profile and insulin resistance in healthy blood donors Francesco Azzaroli Received Received
  SAT-359 CD103+ DCs are a key population in the progression of non-alcoholic steatohepatitis: could DCs represent a novel therapeutic application in NASH? Veronika Lukacs-Kornek Received Received
  THU-359 Non-alcoholic fatty liver disease, hyperglycemia and overweight in the elderly: simple traveling companions or criminal conspiracy? Giampaolo Bianchi Received Received
  FRI-359 New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in mice Katharina Luise Hupa Received Received
  FRI-360 Bone morphogenetic protein (BMP)-9 enhances high glucose-mediated vascular damage Katja Breitkopf-Heinlein Received Received
  THU-360 Presence of metabolic syndrome and low CD4 count are independently associated with liver fibrosis in human immunodeficiency virus-infected patients with non-alcoholic fatty liver Hugo Perazzo Received Received
  SAT-360 Altered methylation of FADS2 in NASH is partly explained by FADS2 genotypes Jussi Pihlajamäki Received Received
  SAT-361 Receptor-interacting protein kinase 3 acts differently according to non-alcoholic fatty liver disease model Waqar Khalid Saeed Received Received
  THU-361 Long term clinical implication of nonobese non-alcoholic fatty liver disease: comparison with metabolically abnormal but normal weight Jae Youn Cheong Received Received
  FRI-361 M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH Ken Song Received Received
  FRI-362 Increased non-shivering thermogenesis had preventive but no therapeutic effects on non-alcoholic steatohepatitis Laurence Poekes Received Received
  SAT-362 Glucagon-like peptide-1 receptor agonists ameliorate inflammation and fibrosis in an optimized rodent NASH model via inhibition of inflammatory macrophage activation Xiaoyu Wang Received Received
  FRI-363 EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis Li-Juan Jiang Received Received
  THU-363 Allele frequency of non-alcoholic fatty liver disease-associated PNPLA3 and TM6SF2 polymorphism in a multi-ethnic population of 60,706 Jake Peter Mann Received Received
  THU-364 Development and validation of automated assessment of liver fibrosis using second harmonic generation microscopy in patients with non-alcoholic fatty liver disease Jason Chang Received Received
  SAT-364 High carbohydrate diet induces acute liver injury, enhanced de novo lipogenesis, inflammation and fibrosis but reversible by M2 macrophage polarization Yong Ook Kim Received Received
  FRI-364 Extracellular vesicle changes in a diet induced model of non-alcoholic fatty liver disease progression and the role of TNF alpha Linda A Ban Received Received
  FRI-365 Kupffer cell pool is maintained by local proliferation and the differentiation of bone marrow monocytes into short-lived monocyte-derived Kupffer cells during non-alcoholic steatohepatitis and recovery Lindsey Devisscher Received Received
  THU-365 A pragmatic algorithm to rule out non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound Javier Ampuero Received Received
  SAT-365 Exosome derived from palmitic acid-treated hepatocytes activates hepatic stellate cells Young-Sun Lee Received Received
  SAT-366 Nano LC- mass spectrometry based proteomic profiling associated with significant fibrosis and collagen deposition in non-alcoholic fatty liver disease (NAFLD) Zobair M Younossi Received Received
  FRI-366 STK25 is a critical determinant in nonalcoholic steatohepatitis Margit Mahlapuu Received Received
  FRI-367 Survival analysis and response to ursodeoxycholic acid in patients with primary biliary cholangitis Montserrat Garcia Retortillo Received Received
  SAT-367 Frequent deterioration in autoimmune hepatitis with acute presentation is not associated with acute AIH but acute exacerbation that could be differentiated from acute AIH by surrogate markers for liver fibrosis Jong-Hon Kang Received Received
  SAT-368 The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time Jorn C Goet Received Received
  THU-368 The anti-human immunodeficiency virus drug rilpivirine decreases hepatic injury in a nutritional model of non-alcoholic fatty liver disease through activation of the IL6/IL22-STAT3-p53 axis Alberto Martí-Rodrigo Received Received
  FRI-368 The role of ethnicity in autoimmune hepatitis Alessio Gerussi Received Received
  THU-369 Anti-fibrotic effect of NV556, a sanglifehrin-based cyclophilin inhibitor, in a preclinical model of non-alcoholic steatohepatitis Alvar Grnberg Received Received
  SAT-369 Prognostic factors for transplant-free survival and external validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy Ka Shing Cheung Received Received
  THU-370 Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids Amalia Gastaldelli Received Received
  SAT-370 Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab Kate Diana Williamson Received Received
  FRI-370 Evaluation of 6-thioguanine therapy in autoimmune hepatitis Floris Frans van den Brand Received Received
  SAT-371 Enrichment of genetic variants in the glucocorticoid receptor signalling pathway in standard treatment failure autoimmune hepatitis Peter Lykke Eriksen Received Received
  THU-371 Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human non-alcoholic fatty liver disease Marta B. Afonso Received Received
  FRI-371 Evaluation of spleen length progression rate as a surrogate marker of clinical outcome in patients with primary sclerosing cholangitis Franziska Jung Received Received
  FRI-372 Dysbiosis of the gut microbiota and increased gut permeability characterize secondary sclerosing cholangitis in critically ill patients (SSC-CIP) Andreas Blesl Received Received
  THU-372 The immunomodulatory activity of the protease-inhibitor SerpinB3 in vivo and in vitro Patrizia Pontisso Received Received
  SAT-372 Long-term outcomes in autoimmune hepatitis patients withdrawing from immunosuppressive therapy Laura Harrison Received Received
  SAT-373 The interpretation of follow-up 3D-magnetic resonance cholangiopancreatography/magnetic resonance imaging in patients with primary sclerosing cholangitis is difficult and highly variable even between experienced specialists Roman Zenouzi Received Received
  THU-373 Small molecule AXL inhibition prevents diet-induced liver fibrosis and inflammation in experimental models of NASH Anna Tutusaus Received Received
  FRI-373 Intradermally applied LPA but not bile salts induce itch and pain in humans depending on the mode of application Andreas E. Kremer Received Received
  THU-374 CD40 activation alleviates steatosis in cultured hepatocytes Antonios Chatzigeorgiou Received Received
  FRI-374 Low platelet count influences the performance of the different biochemical criteria of ursodeoxycholic acid therapy response in primary biliary cholangitis Anna Reig Received Received
  SAT-374 Analysis of shear wave elastography and serum autotaxin as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis – a prospective study Maciej K. Janik Received Received
  SAT-375 Health related quality of life (HRQoL) in patients with AIH: a prospective, single centre study Maciej K. Janik Received Received
  THU-375 The PPARa-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients Bart Staels Received Received
  FRI-375 The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis Anna Reig Received Received
  FRI-376 Primary biliary cholangitis demographics and outcomes: a paradigm shift George Cholankeril Received Received
  THU-376 PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome Brigitte Grouix Received Received
  SAT-376 A population based analysis of prevalence and treatment of autoimmune liver diseases in Germany Marcial Sebode Received Received
  THU-377 A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis Bryan C Fuchs Received Received
  FRI-377 Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT) George N Dalekos Received Received
  SAT-377 Dynamic risk prediction in Primary Biliary Cholangitis using the UK-PBC cohort Marco Carbone Received Received
  THU-378 Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disorders Bryan Laffitte Received Received
  SAT-378 Risk reduction with obeticholic acid in patients not achieving the POISE primary endpoint Maren Harms Received Received
  SAT-379 Patient perspectives on living with autoimmune hepatitis - identifying opportunities to improve care Margaret Corrigan Received Received
  FRI-379 The health burden of primary biliary cholangitis in Switzerland: a cross-sectional study Benedetta Chiara Terziroli Beretta-Piccoli Received Received
  THU-379 Kupffer cell populations share inflammatory tasks and outline a shift in liver resident macrophage population during liver inflammation Christina Mehrfeld Received Received
  THU-380 The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology Claudia P Oliveira Received Received
  SAT-380 Non-invasive evaluation of liver fibrosis in autoimmune hepatitis: still a challenge Maria Lucia Cardoso Gomes Ferraz Received Received
  FRI-380 Increase in age at diagnosis of primary biliary cholangitis over the last 40 years Carla Fiorella Murillo Perez Received Received
  FRI-381 NOD2 variants as novel genetic risk factors for secondary sclerosing cholangitis in critically ill patients Christoph Jüngst Received Received
  THU-381 Influence of UCP3 gene polymorphisms on metabolic syndrome and cardiovascular risk in patients with in non-alcoholic fatty liver disease Claudia P Oliveira Received Received
  THU-382 Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver disease Claus Kremoser Received Received
  SAT-382 Early predictive factors of corticosteroids response in patients with severe/acute or fulminant autoimmune hepatitis Anna Reig Received Received
  SAT-383 Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody positive subjects Stephan Zandanell Received Received
  FRI-383 TNFa as therapeutic target in autoimmune hepatitis Claudia S. Bovensiepen Received Received
  FRI-384 Development of a multivariate model using serum biomarkers to better define primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome Henry H Nguyen Received Received
  THU-384 Role of the intestinal vitamin D receptor in obesity, adipose tissue inflammation and hepatic lipid accumulation Daniel Jahn Received Received
  THU-385 NorUDCA improves liver injury and metabolic situation in mouse models of obesity and steatosis Daniel Steinacher Received Received
  SAT-385 Tolerability and efficacy of 6-mercaptopurin in patients with autoimmune liver disease and azathioprine intolerance Mayada Elnegouly Received Received
  FRI-385 Diagnosis of autoimmune sclerosing cholangitis in children with autoimmune hepatitis Cristina Gonçalves Received Received
  SAT-386 The prognosis ability of GLOBE score in Chinese patients with primary biliary cholangitis Zheyi Han Received Received
  THU-386 Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease Francisco Jorquera Received Received
  SAT-387 Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission Neil Halliday Received Received
  THU-387 Mitochondrial-shaping proteins as specific biomarkers to distinguish alcohol from fat-induced liver toxicity Elena Palma Received Received
  THU-388 Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein Elisabetta Morello Received Received
  SAT-388 Geoepidemiology, clinical manifestations and outcome of a large cohort of primary biliary cholangitis patients in Greece Nikolaos K. Gatselis Received Received
  FRI-388 Autoimmune hepatitis with normal IgG levels at diagnosis: subtype with a higher rate of successful treatment withdrawal? Johannes Hartl Received Received
  FRI-389 Twenty years´ single center experience with non-obstructive sinusoidal dilation Dharma Budi Sunjaya Received Received
  SAT-389 Characteristics of Greek male patients with primary biliary cholangitis Nikolaos K. Gatselis Received Received
  THU-389 Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model Francesco De Chiara Received Received
  THU-390 Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score Francesco Valentini Received Received
  SAT-390 Incidence and prevalence of primary sclerosing cholangitis in a population-based cohort in Finland Nina Barner-Rasmussen Received Received
  FRI-390 Stage of fibrosis and AST Platelet Ratio Index (APRI) as predictors of length of gestation in women with chronic liver disease Enoka Gonsalkorala Received Received
  FRI-391 Autoimmune hepatitis in children and adults: a single centre experience Lisa Perini Received Received
  THU-391 IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis Guillaume Wettstein Received Received
  SAT-392 Cathepsin Z variants are associated with progression to end-stage hepatic failure in Japanese patients with primary biliary cholangitis Nao Nishida Received Received
  SAT-393 T cell interactions with the biliary epithelium in primary biliary cholangitis Rachel Emma Etherington Received Received
  FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease David N. Assis Received Received
  THU-393 Liver iron concentration in patients referred for hyperferritinemia: multicenter analysis of the different groups according to HFE mutations and transferrin saturation index, prediction of liver iron overload in Southern Europe Leire Zubiaurre Received Received
  THU-394 Genotypic-phenotypic profile of Wilson disease patients in Lebanon: Comparison with regional Arab countries Aline Kamil El haddad Received Received
  FRI-394 Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating fecal bile acid composition and signaling Claudia Daniela Fuchs Received Received
  SAT-394 Treg conditioning endows activated Teff with suppressor function in juvenile autoimmune liver disease Rodrigo Liberal* Received Received
  THU-395 Liver iron overload within a UK based population by sex Andrew G Mckay Received Received
  FRI-395 Autoimmune hepatitis patients with poor treatment response have a distinct liver transcriptome: implications for personalised therapy Ben Millar Received Received
  SAT-395 The gut microbiota in liver transplanted primary sclerosing cholangitis patients is characterized by exacerbated dysbiosis Johannes R. Hov Received Received
  SAT-396 miRNA-21-deficiency reduces liver injury, fibrosis and necroptosis in cholestatic bile duct-ligated mice Marta Bento Afonso Received Received
  FRI-396 Obeticholic acid therapy improves cognitive decline in cholestatic liver disease Ben Millar Received Received
  THU-396 Simultaneous non-invasive assessment of liver injury and body composition in alpha1-antitrypsin deficiency Matthias C Reichert Received Received
  SAT-397 Impact of treatment with Telmisartan plus Propranolol on liver tight junctions in MDR2 -/- knockout mice Sigrid Schulte Received Received
  FRI-397 A novel role for BMP9 as a negative regulator of oval cell-mediated regeneration in response to liver damage Annalisa Addante Received Received
  FRI-398 Magnetic resonance imaging findings are related with serum and endoscopic markers of disease activity and severity in primary sclerosing cholangitis Andrea Tenca Received Received
  SAT-398 Expression of the bile acid receptor TGR5 in livers of PSC patients and Mdr2-/- (Abcb4 -/-) mice Maria Reich Received Received
  THU-398 Induced pluripotent stem cell-derived hepatocyte-like cells for study of the TTR protein quality control system Christoph Niemietz Received Received
  THU-399 Dual proteotoxic stress promotes liver tumorigenesis via autophagy overload and activation of p62-mTOR-Nrf2 axis Deniz Kuscuoglu Received Received
  FRI-399 Expression of the oncofetal marker Nope in the regenerating adult murine liver after disruption of interhepatocytic gap junctions with impaired polarisation via bile duct ligation Andrea Bowe Received Received
  FRI-400 ACE2 therapy using a liver-specific AAV vector inhibits chronic biliary fibrosis in mice Indu G Rajapaksha Received Received
  THU-400 Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis Felix Stickel Received Received
  SAT-400 Ablation of Notch-signaling via recombination signal binding protein for immunoglobulin kappa j region knockout in liver induces massive damage by impaired intra-hepatic bile duct morphogenesis, cholestasis and necrosis Umesh Tharehalli Mathada Received Received
  SAT-401 Melatonin levels are significantly decreased in liver tissues of patients with primary biliary cholangitis Urszula Wasik Received Received
  THU-401 A novel algorithm for the management of patients with PiZZ alpha-1 antitrypsin deficiency Grace Dolman Received Received
  THU-402 Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson´s disease Henning Groenbaek Received Received
  SAT-402 MicroRNA expression profiling of peripheral blood B cells from patients with distinct pathologicalstages of primary biliary cirrhosis Xiaomei Wang Received Received
  FRI-402 Pediatric autoimmune hepatitis shows a strong increase of intrahepatic Tregs and an IL-2 associated Treg decline under therapy Jana Diestelhorst Received Received
  SAT-403 Identification of Twinfilin-1 as a key regulator of cholangiocyte biological response to injury: evidence for a possible role of ageing in the progression of cholangiopathies Luca Maroni Received Received
  THU-403 Assessment of bile salt export pump (BSEP) inhibition by BSEP-reactive immunoglobulins from Antibody-induced BSEP deficiency patients using a novel, cell-based assay Jan Stindt Received Received
  FRI-403 Circulating fibroblast growth factor 19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis Jian Luo Received Received
  THU-404 Macrophage activation in patients with wilsons disease – associations with metabolic liver function, liver disease severity and fibrosis Jessica Almida Ellinor Björklund Received Received
  SAT-404 Exploring the role of macrophages in primary sclerosing cholangitis Yung-Yi Chen Received Received
  FRI-404 Exhaustive blood immune phenotype of patients with autoimmune hepatitis Amédée Pablo Renand Received Received
  SAT-405 Dysregulated bile salt homeostasis in patients with chronic intestinal failure on home parenteral nutrition Kiran V.K. Koelfat Received Received
  THU-405 Transcriptomic analysis reveals novel insights into the effect of therapeutic venesection in HFE haemochromatosis John Denis Ryan Received Received
  THU-406 Elevated faecal free iron content in HFE haemochromatosis is reduced by therapeutic venesection John Denis Ryan Received Received
  SAT-406 Bacterial translocation after liver transplantation is associated with biliary complications Jasmijn Wieke Selten Received Received
  FRI-406 A protective role of IL-22BP in acute liver injury Anastasios D. Giannou Received Received
  FRI-407 Neutrophil-to-lymphocyte ratio as an independent predictor of mortality in critically ill cirrhotic patients Caroline Lemaitre Received Received
  THU-407 Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients Karim Hamesch Received Received
  SAT-407 Plasma expansion is key for sustained liver function and viability during normothermic and subnormothermic ex vivo machine perfusion in a rat model Joseph Maria George Gassner Received Received
  THU-408 Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease Karim Hamesch Received Received
  FRI-408 Etiology, outcome and predictors of mortality of viral related acute liver failure: a single centre prospective cohort study Chetan Ramesh Kalal Received Received
  SAT-408 Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury Laura Giuseppina Di Pasqua Received Received
  FRI-409 Combining renewable human liver tissue and novel extracorporeal devices to deliver mammalian liver support David Hay Received Received
  FRI-410 Tapered steroid treatment leads to distinct ALT response patterns in patients with acute severe hepatitis, and may help to distinguish AIH from DILI Elisabeth Mohr Received Received
  THU-410 GANAB mutations: a possible lead to a common hepatic cystogenesis pathway in autosomal dominant polycystic kidney and liver disease? Liyanne Francisca Maria Van De Laarschot Received Received
  SAT-410 MiRNA 181a and 148a plasma levels during acute cellular rejection in liver transplantation Pablo Ruiz Received Received
  SAT-411 Amplification of long noncoding RNA OTUD7AP1, targeted by miRNA 125b, promotes proliferation in hepatocellular carcinoma Ping Chen Received Received
  THU-411 Whole genome sequencing analysis of familial primary sclerosing cholangitis Magdalena Budzinska Received Received
  FRI-411 Liver progenitors and hematopoietic stem cells in acute liver failure and cirrhosis Estela Solanas Received Received
  FRI-412 The Role of chemokine (C-C motif) ligand 2 and the diet influence in the energy metabolism Fedra Luciano Received Received
  SAT-412 Impaired liver regeneration following hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy Rinat Abramovitch Received Received
  THU-413 New molecular classification of hepatoblastoma through an integrative genomic and transcriptomic study Marina Simon-Coma Received Received
  FRI-413 Human hepatobiliary progenitor cells as new candidates for liver cell therapy Giuseppe Mazza Received Received
  FRI-414 IL-33 protects Murine viral fulminant hepatitis by targeting coagulation hallmark protein Fgl2/Fibroleukin expression Haijing Yu Received Received
  THU-414 Variants in TM6SF2 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis Marsha Y Morgan Received Received
  SAT-414 Donation mode impacts on invariant natural killer T cell population leading to scarce iNKT cells in donation after cardiac death liver grafts despite a significant increase in B cells and CD1d expression Yasmeen Giuma Ghnewa Received Received
  SAT-415 The nucleoprotein High-mobility group box 1 critically regulates the immune response to bacterial infection Annika Volmari Received Received
  THU-415 Inherited prothrombotic risk factors in children with extrahepatic portal vein obstruction: a case-control study Massimo Primignani Received Received
  THU-416 Association between GNPAT genotypes and serum iron parameters in C282Y homozygous and C282Y/H63D compound heterozygous patients Moritz Tobiasch Received Received
  FRI-416 Augmenter of liver regeneration protects against carbon tetrachloride-induced liver injury by promoting the autophagy in mice Hongbo Shi Received Received
  SAT-417 Characterisation of cell-type-specific responses in the liver towards IL-1ß by a mathematical model for the p38MAPK/MK2 pathway Stephanie Wolf Received Received
  FRI-417 Formation of bile canaliculi in liver progenitor cell-derived hepatocytes determines clinical outcome of acute-on-chronic liver failure Xiaodong Yuan Received Received
  THU-417 Antibiotics induce remission in pediatric PSC-AIH overlap syndrome allowing corticosteroid-free therapy Pauline Sambon Received Received
  FRI-418 Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure Ji Bao Received Received
  THU-418 Clinical outcomes in polycystic liver disease comparing autosomal dominant polycystic liver disease with autosomal polycystic kidney disease: results of the PLD registry Rene Van Aerts Received Received
  THU-419 GMP-level isolation, quality assessment and biosafety distribution evaluation on human amnion epithelial cell for cell-based therapies Roberto Gramignoli Received Received
  SAT-419 GW4064 alleviate mitochondrial dysfunction and intestinal epithelial cell apoptosis through farnesoid X receptor protected lipopolysaccharides-induced acute intestinal inflammation Hsuan Miao Liu Received Received
  FRI-419 The hepatoprotective cytokine Cardiotrophin-1 (CT-1) attenuates inflammation and prevents the systemic effects of endotoxemia by promoting M2 macrophage polarization Jose Miguel Vélez-Ortiz Received Received
  THU-420 Identification of Src tyrosine kinase as a therapeutic target in cystic fibrosis liver disease using patient specific induced pluripotent stem cells -derived cholangiocytes Romina Fiorotto Received Received
  SAT-421 Impact of sex and apolipoproteins on macrophage activation and Entamoeba histolytica induced liver damage Jill Noll Received Received
  FRI-421 Acute on chronic liver failure (ACLF ) – combining CLIF-SOFA criteria with APASL definition of ACLF enhances prediction of mortality at 1, 3 and 6 months Krishnadas Devadas Received Received
  FRI-422 Development of human liver extracellular matrix hydrogel for three dimensional cell culture and cell transplantation Luca Frenguelli Received Received
  THU-422 Fontan-associated liver disease: diagnosis by elastography and laparoscopic liver biopsy Yohei Koizumi Received Received
  SAT-422 Involvement of TA and ?N p63 and p73 isoforms on the regulation of cell death and tumour recurrence in patients with hepatocarcinoma submitted to liver transplantation Jordi Muntané Received Received
  FRI-423 Exacerbated LPS/GalN-induced liver injury in the stress sensitive Wistar Kyoto rat: possible role of the endocannabinoid system? Marykate Killilea Received Received
  SAT-423 Hepatitis B virus infected cell slows down its cell cycle and proliferation by viral protein and replication Kenichi Morikawa Received Received
  THU-423 Prognostic value and prediction of extra-tumoral microvascular invasion among patients who candidate for hepatectomy or liver transplantation for hepatocellular carcinoma Hidetoshi Nitta Received Received
  FRI-424 Long term mortality is increased in patients surviving acute liver failure without liver transplantation Mhairi C Donnelly Received Received
  THU-424 Ischaemic-reperfusion injury and different risk factors for acute kidney injury in donation after circulatory death liver transplantation. UK single centre study Ilaria Umbro Received Received
  SAT-424 EZH2 methyltransferase and JMJD3/UTX demethylases are involved in hepatocytic differentiation and liver cancer cells plasticity Laura Belloni Received Received
  FRI-425 Genetic ablation of pannexin1 protects against acetaminophen-induced hepatotoxicity in mice Michaël Maes Received Received
  SAT-425 SLU7 is a survival factor for cancer cells working as a mitotic regulator Maddalen Jimenez Received Received
  FRI-426 Hepatocyte-specific deletion of type I interleukin-1 receptor (IL-1RI) attenuates D-GalN/LPS-induced acute liver injury in vivo Nadine Gehrke Received Received
  SAT-426 p38-alpha MAPK couples inflammatory response and proliferation of hepatocytes during acute liver injury Manon Fortier Received Received
  THU-426 Long term prevention of recurrent hepatitis B after liver transplantation using nucleos(t)ide analogs after HBIg discontinuation James Vu Received Received
  THU-427 No increase in graft fibrosis for hepatitis B surface antigen positive patients after liver transplantation using entecavir monotherapy James Yan Yue Fung Received Received
  SAT-427 Amino-functionalized nanoparticles as a platform for mTOR activity modulation in hepatocellular carcinoma Huh7 cell line Mariia Lunova Received Received
  FRI-427 Melatonin protects liver in experimental severe acute liver failure Norma Anair Possa Marroni Received Received
  THU-428 Pregnancy outcomes in the post liver transplant setting: The Irish experience Jayne Doherty Received Received
  FRI-428 Hepatic accumulation and activation of CD8+ T cells aggravate acute liver injury Patricia Maria Niemietz Received Received
  THU-429 Sarcopenia is associated with increased hospital expenditure in patients undergoing major cancer surgery of the alimentary tract Jeroen Van Vugt Received Received
  SAT-429 Reduced miR-26b-5p expression imparts malignant features and help in EpCAM+ liver cancer stem-like cells maintenance via heat shock cognate 71kDa protein (HSC71/HSPA8) Ritu Khosla Received Received
  SAT-430 Implications of Unc5A depletion for hepatocyte survival in chronic liver diseases upon induction of the unfolded protein response Romain Barnault Received Received
  FRI-430 Experimental approach to IGF-1 therapy in acute liver damage: acute injury by carbon tetrachloride in controls and mice with partial IGF-1 deficiency Rocío García de la Garza Received Received
  THU-430 Progression of familial amyloidosis after domino liver transplantation in donor and recipient Johanna Vollmar Received Received
  FRI-431 CX3CR1 modulates the differentiation of monocyte-derived inflammatory dendritic cells in response to hepatic injury Stefania Bruzzi Received Received
  THU-431 Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy Juan Manuel Pascasio Received Received
  THU-432 Donor mannose-binding lectingene polymorphisms increase the risk of severe bacterial infections after liver transplantation Julissa Lombardo Received Received
  FRI-432 External validation of the USALFSG acute liver failure outcome prediction criteria William Bernal Received Received
  SAT-432 Microphysiological systems for studying interactions between the liver, gut and immune system Tomasz Kostrzewski Received Received
  SAT-433 Combined targeting of cholangiocytes and activated stromal cells with a BH3 mimetic ameliorates fibrosis in a mouse model of PSC Anja Moncsek Received Received
  THU-433 Pregnancy outcomes in liver transplant recipients: a single tertiary centre experience Katherine Johanna Arndtz Received Received
  FRI-433 The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF) Zhujun Cao Received Received
  FRI-434 NOX4 dependent activation of hepatic stellate cells with conditioned medium derived from Isoniazid treated hepatocytes: an In-vitro study Abhijit Chowdhury Received Received
  SAT-434 Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling Benedicte Delire Received Received
  THU-434 Effect of diabetes and obesity on short-term outcome after major liver resection Katrin Hoffmann Received Received
  SAT-435 The dynamic roles of hepatocyte and leukocyte-specific CD147 in a progressive liver injury mouse model Christine Yee Received Received
  THU-435 Occult Hepatitis B Virus persistence in liver transplant recipients despite prophylactic hepatitis B immune globulin and potent nucleos/tide analogues therapy Keith CK Lau Received Received
  FRI-435 Alpha toocotrienol causes apoptosis of activated hepatic stelate cells through lysosome mitochondrial axis in INH induced liver fibrosis: an in-vitro study Abhijit Chowdhury Received Received
  FRI-436 TAK1 signaling is essential for NLRP3 activation in mouse drug-induced damage-associated hepatitis Bibo Ke Received Received
  SAT-436 Comparison of liver injury evolution in mouse models Christine Yee Received Received
  THU-436 A pospective study to evaluate the impact of early everolimus on the recurrence of hepatocellular carcinoma after liver transplantation Manuel Rodríguez-Perálvarez Received Received
  SAT-437 CD5L modulates primary human hepatic stellate cells activation Cristina Barcena Received Received
  THU-437 Impact of "rescue allocated" livers on outcomes after liver transplantation: a propensity score matching analysis Mara Disabato Received Received
  FRI-437 The novel macrophage activation marker soluble Mannose Receptor, and soluble CD163, are elevated after acetaminophen intoxication in relation to liver disease severity Cecilie Brøckner Siggaard Received Received
  THU-438 Medical emergency team activation in patients pre- and post-liver transplantation is associated with prolonged length of stay and higher morbidity Marcus Robertson Received Received
  SAT-438 Induced pluripotent stem cells-derived extracellular vesicles shuttle bioactive molecules with anti-fibrotic potential in vitro and in vivo Davide Povero Received Received
  FRI-438 Characterisation of the immune response in patients with drug induced liver injury Giacomo Germani Received Received
  SAT-439 The vacuolar adenosine tri-phosphatase (v-ATPase) proton pump as therapeutic target in human activated HSC Giusi Marrone Received Received
  THU-439 Interferon-free therapy is effective and safe for hepatitis C recurrence in liver transplant hepatitis C virus/human immunodeficiency virus coinfected recipients: A case-control study Xavier Forns Received Received
  FRI-439 Drug-induced effects on mtDNA homeostasis in HepaRG cells and modulation by steatosis Dounia Le Guillou Received Received
  FRI-440 p62/sqstm1 in a drug-induced model of hepatotoxicity: a novel role beyond autophagy Fernando Alegre Received Received
  THU-440 The golden hour: length of total warm ischemia time presages development of severe acute kidney injury after DCD liver transplantation Marit Kalisvaart Received Received
  SAT-440 Kahweol attenuates hepatic fibrosis by inhibition of CTGF via TGF-ß signaling pathways Byoung Kuk Jang Received Received
  SAT-441 Non-sense mediated RNA decay regulates the unfolded protein response during hepatic stellate cell activation Inge Mannaerts Received Received
  THU-441 The use of prophylactic strategies using hepatitis B immunoglobulin for hepatitis B recurrence after liver transplantation in routine clinical practice in Spain. preliminary results of the 1st round of a delphi panel Martín Prieto Received Received
  FRI-441 The S-ademetionine role in the prevention of liver injury in patients with acute leukemias in the polychemotherapy dynamics Igor Skrypnyk Received Received
  FRI-442 Reprogramming of human umbilical cord-derived mesenchymal stromal cells into hepatocyte-like cells by over-expression of hepatocyte nuclear factor 1-alpha Karolien Buyl Received Received
  THU-442 Entecavir or tenofovir monotherapy prevents hepatitis B virus recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal Matteo Angelo Manini Received Received
  SAT-442 Local environment in cirrhotic liver induces Th2 polarization of CD4+ cells which amplify fibrogenesis by activating hepatic stellate cells Johanna Antonia Reissing Received Received
  SAT-443 Ammonia elevates B-neurexin in hepatic stellate cells to escape NK cells activity Johnny Amer Received Received
  THU-443 The incidence of metabolic syndrome and the association with its clinical consequences after liver transplantation Milou Mireille Ter Avest Received Received
  FRI-443 Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity in mice Kengo Tomita Received Received
  FRI-444 Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry Raùl J Andrade Received Received
  THU-444 Differences in the occurrence of metabolic syndrome between patients treated with a calcineurin inhibitor and patients treated with an mTOR inhibitor after liver transplantation Milou Mireille Ter Avest Received Received
  SAT-444 Genome wide methylation profile of liver from patients with severe hepatic fibrosis related to HCV infection Luydson Vasconcelos Received Received
  SAT-445 Autophagy regulates endothelial dysfunction and hepatic fibrosis development Maria Ruart Received Received
  FRI-445 Prevalence and severity of liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients Antonio Grieco Received Received
  FRI-446 Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure Miguel Eugenio Zoubek Received Received
  THU-446 The association of the metabolic syndrome with cardiovascular and cerebrovascular outcomes and renal dysfunction after liver transplantation Olivia FH Ho Received Received
  SAT-446 How gender influences fibrosis regression in a chronic murine model of hepatic injury Marika Crescenzi Received Received
  SAT-447 Activated primary stellate cells show decreased aquaporin 3 expression in parallel with cellular senescence which is restored with PPAR-? agonist establishing quiescence Matteo Tardelli Received Received
  THU-447 Impact of hepatitis C virus treatment on renal function in liver transplant patients Omar Massoud Received Received
  FRI-447 Development of a novel 3D organotypic human HepaRG-based non-invasive imaging platform for pre-clinical drug screening Nicole Jenna Martucci Received Received
  SAT-448 Differential role of NLRP3 inflammasome during acute and chronic cholestatic liver injury Mick Frissen Received Received
  THU-449 Preoperative von willebrand factor - antigen predicts clinical outcome after liver resection: a prospective, international, multicenter trial Patrick Starlinger Received Received
  FRI-449 Drug-induced liver injury: presentations, causes and outcomes: an Egyptian study Omkolthoum Alhadad Received Received
  THU-450 Nurse-led self-management support across two hospitals in liver transplantation: a win-win situation for patients and health care professionals Patrizia Künzler-Heule Received Received
  SAT-450 Immunofluorescence identifies distinct subsets of endothelial cells in the human liver Otto Strauss Received Received
  FRI-450 Influence of host characteristics and pharmacological properties on type of liver injury in hepatotoxicity Raul Andrade Received Received
  FRI-451 Liver progenitor cells significantly contribute to hepatocyte pool in chronic liver injury and cirrhosis: a kinetic study in mice Rita Manco Received Received
  THU-451 History of marijuana use does not affect outcomes on the liver transplant waitlist Prashant Kotwani Received Received
  SAT-451 Inhibition of canonical WNT signaling pathway by ß-catenin/CBP inhibitor ICG001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12 Ruchi Bansal Received Received
  FRI-452 Benzo[a]pyrene and ethanol exert a high toxicity potential in steatotic HepaRG cells: possible role of low NDUFA4L2 expression Simon Bucher Received Received
  SAT-452 Antifibrotic effects of 8-hydroxydeoxyguanosine through the inhibition of NADPH oxidase-derived oxidative stress in vitro and in vivo model of liver fibrosis Seung Kak Shin Received Received
  THU-452 The effect of beta-hydroxy-beta-methyl butyrate supplementation on muscle wasting in patients undergoing liver transplantation: results of preliminary analysis Rosanna Lacetera Received Received
  THU-453 Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry Sara Maggiolo Received Received
  FRI-453 Modelling the impact of targeted interventions on the HCV epidemic in Pakistan: the road to HCV elimination Aaron G. Lim Received Received
  FRI-454 The evaluation of homelessness on HCV treatment outcomes among current and former people who inject drugs Arshia Received Received
  SAT-454 The anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model Shimon Reif Received Received
  SAT-455 A novel 3D Liver Microtissue Model for studying steatosis in vitro Simon Messner Received Received
  THU-455 Implementation of psycho-social electronically-captured patient-reported outcome measures for liver transplant at Mayo Clinic Florida Shehzad Khan Niazi Received Received
  FRI-455 Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection Carmina Pallarés Received Received
  FRI-456 Rapid and large implementation of HCV treatment advances in France, 2007-2015 Christine SILVAIN Received Received
  SAT-456 In bone marrow derived macrophages hepatocyte trigger a marker pattern that is indicative for alternatively activated, regulatory type macrophages Stephanie Wolf Received Received
  THU-456 MELD score > 19 on day five after liver transplant in hepatitis C virus-positive recipients: impact on 90-day graft loss and analysis of predictors Silvia Martini Received Received
  SAT-457 FOXA2 overexpressed adipose derived stem cells attenuated acute liver injury model Yeon Ji Chae Received Received
  THU-457 Favourable virological and clinical outcomes at 1 year after liver transplantation in hepatitis C virus-positive patients who received direct-acting antivirals on the waiting list Silvia Strona Received Received
  FRI-457 Screening for HCV in pregnant women and their partners Charlotta Millbourn Received Received
  THU-458 Risk of late-onset CMV infection after liver transplantation is associated with recipient´s IFNL4 rs12979860 genotype Sona Franková Received Received
  SAT-458 Dabigatran reduces liver fibrosis in thioacetamide-injured rats Yun-Cheng Hsieh Received Received
  SAT-459 A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease Yury Popov Received Received
  THU-459 Evolution of body weight parameters up to 3 years after liver transplantation: the prospective Swiss transplant cohort study Sonja Beckmann Received Received
  THU-460 Liver transplantation does not impact the renal function outcome in Alagille syndrome Tanguy Demaret Received Received
  FRI-460 HCV elimination among people who inject drugs. What would happen after the WHO HCV elimination target is achieved? Ilias Gountas Received Received
  SAT-460 Morphology based assessment of liver fibrosis using a new quantitative metric in abdominal CT scans Andreas Christe Received Received
  FRI-461 Treatment and primary prevention in people who inject drugs (PWID) for chronic Hepatitis C (CHC): Is elimination possible in a high prevalence setting? Ilias Gountas Received Received
  THU-461 The risk of death after liver transplantation due to increasing donor age is highest in young recipients Therese Bittermann Received Received
  SAT-461 Soluble CD147 has an altered expression profile with liver disease progression and in different ethnicities Aimei Lee Received Received
  SAT-462 Non invasive diagnostic modalities to predict advanced hepatic fibrosis in patients with non alcoholic fatty liver disease: a retrospective study Ajeet Singh Bhadoria Received Received
  FRI-462 The impact of broader hepatitis C treatment strategies on population health and social value in England Alison Silverstein Received Received
  THU-462 The burden of healthcare utilization after liver transplantation and its relationship with pre-transplant hospitalization Therese Bittermann Received Received
  FRI-463 Integrating voluntary hepatitis B, C and HIV screening in the compulsory tuberculosis entry screening for immigrants, The Netherlands: a pilot project Janneke Bil Received Received
  SAT-463 Risk of liver fibrosis in patients with Thalasemia major; a tertiary center experience Alghalya A Alomairi Received Received
  THU-463 Recurrence of primary sclerosing cholangitis is associated with lower survival after liver transplantation: an analysis of the European liver transplant registry data base Thijmen Visseren Received Received
  SAT-464 Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen Received Received
  FRI-464 Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study Jeffrey Victor Lazarus Received Received
  THU-465 A glycomic serum marker analysed at one week after liver transplantation is an independent predictor of graft loss during the first year after liver transplantation Xavier Verhelst Received Received
  FRI-465 Do elevated liver values necessarily indicate a health problem or could poorly defined upper limits of normal be an issue? Alanine aminotransferase and gamma-glutamyltransferase depend strongly on age Johannes Wiegand Received Received
  SAT-465 Acoustic Radiation Force Imaging the Fontan liver – feasibility and reproducibility Amanda J Nicoll Received Received
  THU-466 Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation Xavier Verhelst Received Received
  SAT-466 The clinical utility of non-invasive tests in cirrhosis: results of decision analysis modelling Avik Majumdar Received Received
  FRI-466 Hepcheck Dublin: homeless, hepatitis C & competing priorities John S Lambert Received Received
  FRI-467 Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia Julie Bouscaillou Received Received
  SAT-467 Prevalence of fatty liver and fibrosis in patients with type 2 diabetes mellitus and previously undetected liver disease as assessed by transient elastography and ultrasound Ivica Grgurevic Received Received
  THU-467 Inhibition of NADPH oxidase-2 and P38 mitogen activated protein kinase suppresses acrolein aggravated hepatic ischemia reperfusion injury through neutrophil extracellular traps Arumugam Suyavaran Received Received
  SAT-468 Non-invasive detection of patients with nonalcoholic steatohepatitis at risk of adverse liver outcomes Jagpreet Chhatwal Received Received
  FRI-468 Smoking and metabolic syndrome components are independent predictors of mortality in patients with chronic liver disease in the United States Karn Wijarnpreecha Received Received
  SAT-469 ECV-associated miRNA levels as non-invasive biomarkers for early-stage HBV/HCV-induced liver fibrosis Joeri Lambrecht Received Received
  THU-469 Herpesviruses in bile: Increasing sensitivity by testing the right compartment Conrad Rauber Received Received
  FRI-469 Chronic hepatitis C diagnosis increases sick leave and disability pension Jonas Söderholm Received Received
  THU-470 Simulated microgravity significantly impacts the differentiation and metabolism of human hepatic and biliary tree stem/progenitor cells Daniele Costantini Received Received
  FRI-470 Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians Mahmud Mahamid Received Received
  SAT-470 Non-invasive fibrosis markers are independent predictors of mortality among U.S. adults with nonalcoholic fatty liver disease Karn Wijarnpreecha Received Received
  SAT-471 Association between non-invasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease in the United States Karn Wijarnpreecha Received Received
  THU-471 The role of recipient epithelial cells in regeneration after liver transplantation: different kinetics of chimerism for hepatocytes and bile duct epithelial cells Floris Johan Maria Roos Received Received
  FRI-471 A survey on non-alcoholic fatty liver disease amongst general practitioners: time to bridge the gap between hepatologists and primary care Jef Verbeek Received Received
  FRI-472 Identification of the healthy ranges for enhanced liver fibrosis score Agostino Colli Received Received
  THU-472 Approaches to fabricate practical recellularized liver graft using primary liver cells-our seeding method for optimal distribution of parenchymal and endothelial cells Hidenobu Kojima Received Received
  SAT-472 Non-invasive evaluation of clinically significant portal hypertension: validation of two novel algorithms combining liver and spleen stiffness using shear-wave elastography in a large independent cohort of patients with cirrhosis Laure Elkrief Received Received
  SAT-473 Elastogram quality assessment score in vibration controlled transient elastography: diagnostic performance compared to digital morphometric analysis of liver biopsy Leandro Cesar Mendes Received Received
  THU-473 Human leukocyte antigen matching in living donor liver transplantation: does it affects the outcome? Iman Montasser Received Received
  FRI-473 Non-steroid anti-inflammatory drugs for biliary colic Mirella Fraquelli Received Received
  SAT-474 Ultrasound-measured visceral adipose tissue correlates with risk factors, severity and co-morbidities of NAFLD better than waist circumference Lucia Napoli Received Received
  THU-474 Bile duct strictures after liver transplantation are associated with a donor glypican-6 polymorphism linked to the biliary stem cell niche Jasmijn W. Selten Received Received
  FRI-474 Hepatitis prevention, control, and elimination program in Mongolia: National hepatitis elimination program in a country with the highest burden of viral hepatitis in the world Naranbaatar Dashdorj Received Received
  FRI-475 Reaching hepatitis C virus elimination targets in Australia requires use of complementary cost-effective interventions along the care cascade Joseph Doyle Received Received
  SAT-475 Controlled attenuation parameter predicts steatosis in alcoholic liver disease and correlates with poor metabolic phenotype and cardiovascular risk: A biopsy-controlled multicenter study Maja Thiele Received Received
  THU-475 The non-alcoholic fatty liver disease liver fat score is associated with liver disease mortality in the United States population Aynur Unalp-Arida Received Received
  SAT-476 Transient elastography correlates with liver fibrosis and markers of portal hypertension in PSC: Laennec score-based analysis of explanted livers Marcin Krawczyk Received Received
  FRI-476 Eliminating hepatitis C virus from HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour Joseph Doyle Received Received
  THU-476 The impact of bariatric surgery on nonalcoholic fatty liver disease and cardiovascular risk utilizing non-invasive measures Carmit Netanel Received Received
  THU-477 Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease Caussy Cyrielle Received Received
  FRI-477 Implementing the WHO Global Health Sector Strategy on Viral Hepatitis in Denmark – modeling the effects of community-based care on the elimination of HCV by 2030 Ole Henriksen Received Received
  SAT-477 Effect of meal ingestion on liver stiffness and controlled attenuation parameter Marco Silva Received Received
  FRI-478 An alternative screening strategy for hepatitis C virus infection among americans not belonging in the baby boomer birth cohort Prowpanga Udompap Received Received
  THU-478 Noninvasive diagnosis of hepatic fibrosis by biofibroscore in patients with chronic hepatitis C virus infection Chen-Hua Liu Received Received
  SAT-478 Dynamics of liver stiffness and serum IP10 levels among patients with chronic hepatitis C who achieved SVR with DAA treatment Cristina Rigamonti Received Received
  SAT-479 Predictors of persistence of clinical significant portal hypertension in patients with HCV liver cirrhosis following 3D therapy and SVR Maria C. Speranta Iacob Received Received
  THU-479 Screening for nonalcoholic fatty liver disease by transient elastography with controlled attenuation parameter in unselected patients with inflammatory bowel disease Chiara Saroli Palumbo Received Received
  FRI-479 Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France Sylvie Deuffic-Burban Received Received
  FRI-480 Systematic screening in an ongoing cross-sectional epidemiological study on hepatitis C high-risk populations in Trondheim city, Norway Therese Svendsen Received Received
  THU-480 Liver stiffness based model predicts portal hypertension, esofageal varices and hepatocellular carcinoma in caucasian patients with hepatitis B virus-related cirrhosis responsive to antiviral therapy Claudia Chialà Received Received
  SAT-480 Circulating Fibroblast Activation Protein activity as a liver fibrosis biomarker in NAFLD Geoffrey William McCaughan Received Received
  THU-481 Variability of intrahepatic fat distribution and optimal measurement of hepatic fat amount using MRI proton density fat fraction Dae Won Jun Received Received
  SAT-481 Point shear wave elastography (ElastPQ) is a reliable non-invasive tool for the diagnosis and characterisation of portal hypertension Matteo Rosselli Received Received
  FRI-481 Prevalence of end of life criteria in patients with liver disease in South West England Ulrich Thalheimer Received Received
  FRI-482 High levels of transmission of HCV infection among people who inject drugs in Greece Vana Sypsa Received Received
  SAT-482 Prospective comparison of shear-wave elastography, CAP and conventional ultrasound for non-invasive detection and grading of steatosis Maxime Ronot Received Received
  THU-482 Acoustic radiation force impulse elastography combined with ultrasound spleen platelets portal vein doppler score in variceal screening: Improved performance compared with baveno VI criteria for avoidance of endoscopy in cirrhotics David Ian Sherman Received Received
  THU-483 The role of serial ARFI elastography in confirming remission in active autoimmune liver disease: a controlled study with long follow up David Ian Sherman Received Received
  FRI-483 High prevalence of chronic hepatitis C in injecting drug users in Tanzania, East Africa: a neglected burden of disease Zameer Mohamed Received Received
  FRI-484 Novel PCR-based method to detect fungal colonization of ascites, bile and duodenal fluid in patients with acute on chronic liver failure (ACLF) or after orthotope liver transplantation (OLT) Adam Herber Received Received
  THU-484 ElastPQ shear-wave elastography compared to fibroscan transient elastography for fibrosis staging in patients with NAFLD Davide Roccarina Received Received
  SAT-484 The point of care 13C-Methacetin breath test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology Mitchell L. Shiffman Received Received
  SAT-485 The hidden burden of hepatitis C related advanced liver disease in the community Nadeem Iqbal Received Received
  THU-485 Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals Dina Attia Received Received
  FRI-485 Model for end stage liver disease score dynamics in NASH patients awaiting liver transplantation and waitlist outcomes W. Ray Kim Received Received
  FRI-486 Model for end stage liver disease score dynamics in patients awaiting liver transplantation and waitlist outcomes W. Ray Kim Received Received
  THU-486 Urinary metabotypes in patients with chronic hepatitis C virus infection as revealed by nuclear magnetic resonance-based metabolomics Elisa Biliotti Received Received
  SAT-486 Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan) Nataliia Marunchyn Received Received
  SAT-487 How to combine blood test and elastography to stage liver fibrosis in chronic hepatitis C? Paul Cales Received Received
  FRI-487 External validation of the HCC-MELD score for patients with hepatocellular carcinoma waiting for liver transplantation Alessandro Vitale Received Received
  THU-488 Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C Ezequiel Mauro Received Received
  SAT-488 Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy Puneet Puri Received Received
  FRI-488 Sofosbuvir based therapy for recurrent hepatitis C post liver transplantation: an Egyptian experience Ayman Yosry Received Received
  FRI-489 The impact of multidisciplinary support to alcohol misusers at risk of alcohol relapse after liver transplantation Barbara Lattanzi Received Received
  THU-489 Normal values of liver stiffness as measured by transient elastography: pooled individual participant data meta-analysis from 26 studies and 14,883 participants Kymberly D. Watt Received Received
  THU-490 Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens Federico Ravaioli Received Received
  SAT-490 Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with Non-alcoholic fatty liver disease Samuel Joseph Daniels Received Received
  FRI-490 A tele-health based technology can effectively triage liver transplant evaluations and minimize futile invasive testing in an integrated health deliver system Binu John Received Received
  FRI-491 Prospective comparison of coefficient attenuation parameter and ultrasound for grading graft steatosis in a large real-life cohort of liver-transplant patients Christiane Stern Received Received
  SAT-491 Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease Sander Lefere Received Received
  THU-491 DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods Federico Ravaioli Received Received
  THU-492 Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients Federico Ravaioli Received Received
  FRI-492 Cardiovascular risk and coronary artery calcium score after liver transplantation: study at fouth year Claudia P Oliveira Received Received
  SAT-492 The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and transient elastography in patients with chronic liver disease Sang Gyune Kim Received Received
  THU-493 Which are the best cut-off values for predicting different stages of liver fibrosis for 2D-SWE.GE in daily practice? Felix Bende Received Received
  SAT-493 Circulating serum exosomal microRNA-203 as a non-invasive biomarker for predicting prognosis in hepatocellular carcinoma Se Young Jang Received Received
  FRI-493 Auxiliary liver transplantation for acute liver failure: a model of competition between regeneration and apoptosis Clémence Hollande Received Received
  FRI-494 Preoperative intra-platelet serotonin levels are associated with early disease recurrence after liver resection in humans David Pereyra Received Received
  THU-494 Non-invasive assessment of liver fibrosis by point share wave elastography in primary biliary cholangitis: comparison with fibroscan and fibrosis scores Francesca Saffioti Received Received
  SAT-495 Community Approach Targeting Cirrhosis and Hepatocellular carcinoma (CATCH): Community prevalence of advanced fibrosis in viral hepatitis Stephen Bloom Received Received
  THU-495 Predictive value of S-GGT for severe liver disease in the general population – a population-based cohort study with over a decade of follow-up Fredrik Åberg Received Received
  SAT-496 Transient Elastography has limited efficacy for fibrosis assessment in End Stage Renal Disease patients on maintenance haemodialysis with suspected liver disease Sunil Taneja Received Received
  THU-496 Assessment of fibrosis markers in a large cohort of chronic hepatitis B patients in Ethiopia Hailemichael Desalegn Received Received
  FRI-496 Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation Ezequiel Mauro Received Received
  FRI-497 Leaky gut does not affect the risk of infectious complications and survival in liver transplant recipients: comparison with cirrhotic patients and healthy individuals Francesca Romana Ponziani Received Received
  SAT-497 Point shear wave elastography method for assessing liver stiffness in different etiologies of liver diseases – a prospective study Tarek Saadi Received Received
  SAT-498 The novel point shear-wave elastography method ElastPQ is accurate for non-invasive evaluation of liver fibrosis and portal hypertension Theresa Bucsics Received Received
  THU-498 Non-invasive multiparametric MRI (LiverMultiScanTM) effectively excludes NASH and liver fibrosis in at risk patients Rajarshi Banerjee Received Received
  FRI-498 Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation Rob Bielen Received Received
  THU-499 Characterisation of liver fat in the UK biobank cohort Rajarshi Banerjee Received Received
  SAT-499 Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography Thomas Karlas Received Received
  SAT-500 The effect of liver steatosis on non-invasive measurement of liver iron concentration by spin-density projection assisted R2-MRI (FerriScan) Tim Guy St Pierre Received Received
  THU-500 Predicted prevalence and stratification of non-alcoholic fatty liver disease in a large population using non-invasive multiparametric MRI Rajarshi Banerjee Received Received
  FRI-500 Acute rise in delta model for end-stage liver disease as a prognostic risk factor for post-transplant mortality: an analysis of a national registry George Cholankeril Received Received
  THU-501 Novel mapping of fibrosis and hepatic inflammation in NASH patients with dual R2 MRI relaxometry Claudia P Oliveira Received Received
  SAT-501 Clinical and prognostic associations of liver volume determined using computed tomography in patients with cirrhosis Tiong Yeng Lim Received Received
  THU-502 Hepatic iron overload analysis bymagnetic resonance imaging in a non-alcoholic fatty liver disease population Claudia P Oliveira Received Received
  SAT-502 Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein as a serum biomarker for disease severity in non-alcoholic fatty liver disease Wah Kheong Chan Received Received
  THU-503 Serum immunoglobulin levels are related to histological severity of primary biliary cholangitis Huan Wang Received Received
  FRI-503 Laparoscopic liver resection for hepatocellular carcinoma located in segments 7 or 8 Hanisah Guro Received Received
  SAT-503 Collagen formation and degradation biomarkers identify advanced fibrosis in NASH patients Yi Luo Received Received
  SAT-504 A novel non-invasive Golgi protein 73 (GP73)-based model accurately diagnoses significant fibrosis in chronic liver disease Zhujun Cao Received Received
  THU-504 Dynamic of liver stiffness values by means of transient elastography in patients with hepatitis C virus liver cirrhosis undergoing Interferon free treatment Ioan Sporea Received Received
  FRI-504 Effects of liver transplantation on cardiac function in patients transplanted for NASH cirrhosis Haripriya Maddur Received Received
  LBP-505 Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe Alison D. Marshall